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Introduction and aim of the study
8THE MULTIPLE ORGAN DYSFUNCTION SYNDROME
Care of critically ill patients has progressed significantly since world war two.
An evolving ability to support vital organ system function during a period of
otherwise lethal physiologic insufficiency has changed the process of hospital
care. The development of techniques of hemodialysis, positive pressure
ventilation and cardiovascular support have transformed life-threatening illness
from a rapidly progressing lethal event to a chronic state that appears potentially
survivable. Advances in the support of vital organ function have led to the
institution of intensive care units and spawned an entirely new specialty, that of
intensive care medicine.
Unfortunately, our increased ability to keep patients alive has yielded a new
phenomenon: the sequential failure of organ systems that usually occurs after a
lag period of days to weeks after various physiologic insults, which may include
pancreatitis, trauma, burns, shock, severe infection, aspiration, multiple blood
transfusions, and pulmonary contusions 1,2. Previously known as “Multiple
Organ Failure” (MOF), the name of this phenomenon has evolved to “Multiple
Organ Dysfunction Syndrome” (MODS), because “dysfunction” is thought to be
a better description of the continuum of changes that occur in organ systems.
MODS is defined as the presence of altered organ function in a severely ill
patient so that homeostasis cannot be maintained without intervention 3.
Regardless of the cause, MODS typically consists of the sequential dysfunction
of several organ systems, beginning with the lungs and followed by hepatic,
intestinal, renal, hematological and eventually cardial dysfunction, although the
exact order may vary because of preexisting disease or the nature of the
precipitating insult 4 5. If fitting to specific definitions, the respiratory
dysfunction is referred to as the acute respiratory distress syndrome (ARDS) 6.
Lung dysfunction may already be found within hours after the insult, and
9consists of tachypnea and respiratory alkalosis, followed by a decrease in arterial
pO2.
Despite the astounding scientific progress in our understanding of infection,
sepsis, trauma, cell and organ injury, shock, acute renal failure and acute
respiratory failure, MODS remains the principal cause of death in surgical
intensive care units. It is responsible for 50 to 80% of all surgical intensive care
unit deaths and costs exceed $150.000 per patient 4. Certain factors increase the
probability for patients to develop MODS after an initial insult. These risk
factors include inadequate or delayed resuscitation, a persistent infectious or
inflammatory focus, baseline organ dysfunction (e.g. renal insufficiency), an age
of  >65 years, alcohol abuse, bowel infarction, malnutrition, diabetes, cancer, the
presence of hematoma and the use of steroids 7. Once MODS develops, the
number of dysfunctioning organ systems is a crucial prognostic factor. Single-
organ dysfunction has a mortality of 30 to 40%, whereas two- and three-organ
dysfunction have mortalities exceeding 60 and 90%, respectively 7.
PATHOPHYSIOLOGY OF MODS
There are two clinical observations that strongly indicate that MODS is a
systemic process. First, the organs where damage occurs are not necessarily
directly injured or involved in the primary disease process. Second, there is
usually a lag phase of days to weeks between the primary insult and the
development of remote organ dysfunction. These observations suggest that
endogenous circulating factors are involved in the pathophysiology of MODS.
It is now generally believed that MODS is the result of a generalized
inflammatory response. Inflammation is a rapid, highly amplified controlled
humoral and cellular response to injury. The complement, kinin, coagulation and
fibrinolytic cascades are triggered simultaneously with the activation of
phagocytes and endothelial cells. This essentially local response is effective as
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long as the inflammatory process is regulated appropriately to keep cells and
mediators sequestered. There are four major events in the inflammatory process:
vasodilatation, increased micro-vascular permeability, cellular
activation/adhesion and coagulation. Vasodilatation and increased micro-
vascular permeability at the site of injury increase locally available oxygen and
nutrients and produce heat, swelling and tissue oedema. The local hemodynamic
changes cause the five classical symptoms associated with local inflammation:
rubor (erythema), tumor (edema), calor (heat), dolor (pain) and functiolaesa
(disturbed function).
Cytokines are the physiological messengers of the inflammatory response. The
principal molecules involved are tumor necrosis factor α (TNF-α), interleukins,
interferons and colony stimulating factors. Polymorphonucleocytes (PMNs),
monocytes / macrophages and endothelial cells are the principal cells involved
in the inflammatory response. Leukocyte activation leads to increased leukocyte
aggregation and tissue infiltration within the microcirculation where these
leukocytes (PMNs and macrophages) undergo a respiratory burst, and increase
their oxygen consumption and production of cytokines and other inflammatory
mediators such as nitric oxide 8.
Localized inflammation is a physiological protective response, which is
generally tightly controlled by the body and usually limited to the site of injury.
Loss of this local control or an overly activated response results in an
exaggerated systemic response, a phenomenon which is clinically identified
today as the systemic inflammatory response syndrome (SIRS) 8. SIRS may be
initiated by infection or by non-infectious causes such as trauma, auto-immune
reactions, cirrhosis and pancreatitis. SIRS may result in organ dysfunction,
which can progress to MODS 8. The first descriptions of MODS have
emphasized its common association with occult or poorly controlled infection 9.
However, our laboratory was the first to suggest that a generalized inflammatory
response, rather than infection per se, is the cause of MODS 10. Although
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common in patients with MODS, infection is not necessarily present and
frequently follows rather than precedes the development of the syndrome 2,11.
Although it is difficult to differentiate the clinical manifestations of
inflammation from the infections that are commonly their cause, it can be shown
that the severity of the inflammatory response rather than the presence or
absence of infection is the more important determinant of ICU survival 12.
Cohort studies in critically ill patients show that increased circulating levels of
pro-inflammatory cytokines such as TNF-α and IL-6 in response to
inflammatory stimuli are associated with organ dysfunction and an increased
risk of death 13-16. Although the synthesis and release of biochemical mediators
of inflammation is characteristic of both experimental and clinical sepsis, the
mechanisms which cause these molecules to induce organ injury are largely
unknown. In severe sepsis, proinflammatory cytokines exert many biological
effects, such as activation of coagulation and enhanced formation of thrombin
and fibrin clots. So far, activated protein C, an endogenous fibrinolytic agent,
represents the only specific therapeutic modality apart from antibiotics that has
been shown to improve mortality in severe sepsis and septic shock 6.
Until we gain a better understanding in this field, our ability to devise rational
and effective therapeutic interventions will be seriously constrained.
Intervention studies in humans will probably not be very successful before pre-
clinical experimental studies and animal studies have provided a better
fundamental insight in the molecular and cellular mechanisms that lead to
MODS.
 AIM OF THE STUDY
Investigations into the mechanisms of MODS necessitate the collection of tissue
samples and invasive procedures that cannot be performed in humans. As a
substitute, an animal model for MODS has been developed by our research
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group. In 1986, Goris and coworkers have described a model that has been
recognized as the only model so far which shares a number of characteristics
with human MODS 11. It is called the zymosan induced generalized
inflammation (ZIGI) model and has been adopted by other research groups as
well. Chapter 2 provides an overview of the scientific literature concerning the
ZIGI model.
The purpose of the thesis was to examine mediators and mechanisms involved in
the pathogenesis of MODS in mice. The following questions have been
addressed:
-What is the expression of mRNA for a number of inflammatory cytokines in
various organs during the development of MODS (chapter 3)?
-Can MODS progress in animals without endogenous TNF-α (chapter 4)?
-Can treatment with pentoxifylline, a compound that inhibits the production of
TNF-α and possibly that of other pro-inflammatory cytokines, mitigate the
development of MODS (chapter 5)?
-Is nitric oxide, produced by inducible nitric oxide synthetase (iNOS), an
essential mediator in the development of organ damage (chapter 6)?
-Are enzymes from the matrix metalloproteinases (MMP) family upregulated in
the various organs during evolving organ damage (chapter 7)?
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Zymosan-induced generalized inflammation
in mice: experimental studies into
mechanisms leading to the multiple organ
dysfunction syndrome.
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ABSTRACT
Patients suffering from the multiple organ dysfunction syndrome (MODS)
comprise a heterogeneous population, which complicates research in its
pathogenesis. Elucidation of the mechanisms involved in the development of
MODS will ultimately necessitate the collection of tissue samples and the
performance of invasive procedures. These requirements greatly reduce the
possibilities for research in human subjects. Therefore, an animal model for
MODS is a necessary and valuable tool. In the mid-1980s, the zymosan-induced
generalized inflammation (ZIGI) model was introduced. Intraperitoneal injection
of zymosan in mice or rats leads, in the course of 1-2 weeks, to increasing organ
damage and dysfunction. This model has been recognized as the one which
features best resemble human MODS and it has been used widely to study
systemic inflammation in relation to organ failure. This review describes the
ZIGI model and gives an overview of the results obtained.
17
INTRODUCTION
The Multiple Organ Dysfunction Syndrome (MODS) became a problem in
intensive care units (ICUs) after improvements in hemodynamic support and
fluid resuscitation led patients to survive the acute phase of shock and sepsis.
Thirty years after its initial description 1, the mortality of MODS remains
essentially unchanged. MODS still is the principal cause of morbidity and
mortality for patients admitted to an ICU. The costs of its treatment are
enormous 2,3.
MODS has been documented to occur after a number of diverse clinical
conditions, such as infection, shock, trauma and pancreatitis. Patients suffering
from MODS thus comprise a heterogeneous population, which complicates
research into its pathogenesis. Still, the development of rational interventions
requires insight in the pathological processes involved. Elucidation of the
mechanisms involved in the development of MODS will ultimately necessitate
the collection of tissue samples and the performance of invasive procedures.
These requirements greatly reduce the possibilities for research in human
subjects. Therefore, an animal model for MODS is a necessary and valuable
tool. In 1986, Goris and coworkers 4 have first described a model that has
subsequently been recognized as the one which features best resemble human
MODS. This review describes the model and aims to arrange the results reported
in a variety of studies.
ZYMOSAN
Zymosan is a substance derived from the cell wall of the yeast Saccharomyces
cerevisiae. It is composed of polysaccharide chains of various molecular weight,
containing approximately 73% polysaccharides, 15% proteins, 7% lipids and
inorganic components 5. When injected into animals, it induces inflammation by
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inducing a wide range of inflammatory mediators. These include activated
components of the complement system 6, prostaglandins and leukotrienes 7,
platelet aggregation factor 8, oxygen radicals 9 and lysosomal enzymes 10. Also,
zymosan directly activates macrophages 11. Toll-like receptor (TLR)-2 has been
shown to be involved in zymosan-induced signaling 12. After zymosan is
phagocytosed, macrophages release lysosomal enzymes 13, reactive oxygen
metabolites, arachidonic acid 14 and tumor necrosis factor-α (TNF-α) 15. Because
zymosan is not degradable, phagocytosis by macrophages results in a prolonged
inflammatory response. This effect can be enhanced by the use of mineral oil as
a carrier.
THE ZYMOSAN-INDUCED GENERALIZED INFLAMMATION (ZIGI)
MODEL
Most experimental models of critical illness, such as infusion of endotoxin or
bacteria or cecal ligation and puncture, are essentially acute models for sepsis.
Almost invariably, they are used to improve or investigate short-term mortality
and organ failure. The observation period consists of hours rather than days.
Since it usually requires at least 5-7 days after the initial event to fully develop
MODS in critically ill patients, chronic models are likely to be more relevant to
the human situation. To date, the ZIGI model is the only long-term experimental
animal model for MODS.
Intraperitoneal injection of zymosan in a high dosage (0.8-1.0 mg/ g body
weight) in rats and mice results in a three-phasic illness. After the injection of
zymosan the animals develop an acute peritonitis. They are very ill during the
first two days, as reflected by a ruffled fur, diarrhea, lethargic behavior and a
decrease in body weight. During this phase, the animals are leukopenic and
oxygen consumption 4, myeloperoxidase levels (indicating neutrophil
recruitment) in lungs and peritoneum 16,17 and endothelial permeability 18 are
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increased. Bacterial translocation to the peritoneal cavity and mesenteric lymph
nodes is found regularly 19. The mortality in this phase is usually between 10 and
35%. Because the early mortality suddenly increased dramatically a few years
ago (up to 100%), most likely as the result of changing conditions within our
central animal facility, we have introduced a small modification to the initial
model 20. This modification consists of an aseptic intraperitoneal injection of 40
µg lipopolysaccharide (LPS) six days before the intraperitoneal injection of
zymosan in mice. LPS activates a variety of cell types, such as
monocytes/macrophages, endothelial cells and some epithelial cells 21.
Triggering the immune system by a small dose of LPS prevents an excessive
response to zymosan six days later, because the mortality rate of the animals in
the first days after zymosan returned to normal (below 30%).
In the second phase of the model (day 3 to 5) the condition of the surviving
animals appears to return to normal, as reflected by the display of natural
curiosity, grooming, a smooth fur, and disappearance of diarrhea. Body
temperature is restored to normal and animals gain weight again. There is no
mortality in this phase. From approximately day 7 onwards, animals enter a
MODS-like phase, characterized by lethargic behavior, breathing difficulties,
progressive weight loss, and a substantial decrease in body temperature.
Between day 7 and day 14 the mortality is between 20 and 30%.
Histopathological changes in various organs indicate a gradual development of a
generalized inflammatory response with extensive tissue injury 22. Massive
hemorrhages develop in the lungs. The liver displays progressive accumulation
of macrophage-like and mononuclear cells, forming granuloma-like structures.
The spleen displays great changes in red and white pulp with increased numbers
of megakaryocytes and plasma-like cells 23. Organ damage in this phase is also
reflected by an increase in the wet weight of lung, liver, and spleen 23, indicating
tissue oedema. Very recently, we have found that the activity of matrix
metalloproteinases (MMPs), which class of enzymes catalyzes connective tissue
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degradation, is upregulated during the development of organ damage 24. During
the third phase, the course of body weight and body temperature –and,
obviously, mortality- are quantitative measures of illness. Figure 1 shows the
course of these parameters during a typical experiment. At the end of the
experiment, organ weight or (semi-) quantitative histology yield good
parameters for organ disease.
BACTERIA
Initially, MODS was believed to occur only after a bacterial infection or
endotoxemia. Zymosan causes an intense inflammatory response without
administration of exogenous bacteria or modification of the normal bacterial
flora. This allows examination of the possible role of bacterial translocation in
the development of MODS. Studies in rats have shown that in the ZIGI model
bacterial translocation is common 19,22,25-28 but not essential for the development
of organ damage. Using germ-free rats 4 and selective decontamination of the
gastrointestinal tract of normal rats 25, Goris et al. have demonstrated that
zymosan is capable of inducing MODS in the absence of bacteria. In
streptomycin-decontaminated rats, survival was 100% despite massive
translocation of streptomycin-resistant enterobacteriacea 29. Streptomycin has
been shown to prevent macrophage activation 30. Also, it has been reported that
mice that are hyporesponsive to endotoxin remain only in a slightly better
condition than endotoxin-sensitive mice 31, which suggests that endotoxin is not
essential in the pathogenesis of MODS. Elimination of macrophages lowers the
systemic toxic response (as indicated by the degree of conjunctivitis, ruffled fur,
lethargy and diarrhea) and subsequent mortality, despite the fact that systemic
bacterial translocation is enhanced 32. Taken together, these observations support
the hypothesis that, in this model, MODS is the result of a generalized
inflammatory response, rather than infection per se.
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Figure 1. Survival and clinical symptoms in the ZIGI model. Survival (A), body temperature
(B) and relative body weight (C) of C57BL/6 mice (closed circles, n=30) in comparison with
untreated control mice (open circles, n=6). Day –6: LPS i.p.; day 0: zymosan i.p. Relative
body weight was calculated as (body weight/body weight at day 0)*100%. Data represent
average values + SD.
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CYTOKINES
Since MODS is now believed to be the result of a generalized inflammatory
response, increasing attention has been paid to the role of pro-inflammatory
mediators in its pathophysiology. The (over)expression of these mediators,
which include cytokines, complement factors and reactive oxygen species,
results in increased peripheral dilatation, leukocyte/endothelial cell activation,
excessive microvascular permeability and accelerated microvascular clotting 33.
These responses contribute to the development of profound changes in the
various organs, which may eventually lead to MODS 34,35.
Zymosan induces secretion of TNF-α, IL-1β, IL-6 and IL-8 by macrophages 36.
Three mechanisms are known by which zymosan can trigger cytokine secretion.
Firstly, normal serum contains IgG immunoglobulins that bind to zymosan 37.
The complexes formed this way activate the classical pathway of the
complement system, and may induce TNF-α release by cross-linking
macrophage Fc receptors 38. Secondly, zymosan activates complement via the
alternative pathway 39. The subsequent binding of C3b/iC3b to zymosan
particles enables uptake of the particles via complement receptors on
macrophages and granulocytes. Thirdly, the binding of C3b to the zymosan
surface results in increased conversion of C5 to C5a 40, which triggers TNF-α
release 41. Whereas these pathways act synergistically to induce TNF-α release
42, the mechanisms by which other cytokines are induced by zymosan are less
clear. Probably IL-1β and IL-6 release by macrophages is partly dependent on
exposure to TNF-α. A strong increase in the secretion of IL-8 is induced by
phagocytosis of zymosan by monocytic cells 43.
In zymosan-induced organ damage, TNF-α appears to play an important role.
Jansen et al. 44 found that plasma TNF-α and interleukin (IL)-6 concentrations
were transiently increased during the first 24 hours after administration of
zymosan. After eight days a prominent peak of biologically inactive TNF-α was
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observed. There also was a significantly enhanced LPS-stimulated production of
TNF-α by peritoneal cells over the entire experimental period. The plasma TNF
levels did not correlate with the peritoneal macrophage TNF production levels,
especially in the second phase of illness, when no plasma TNF could be
detected. Peritoneal macrophage TNF production was very high. Volman et al.
45 found an increased expression of TNF-α, IL-1β, IL-6, IL-12 and interferon- γ
(IFN-γ) mRNA in a time-dependent pattern in several organs. This increase was
most pronounced for TNF-α in the lungs and liver. Moreover, in TNF-
α/lymphotoxin-α knockout mice 20 and in TNF receptor p55 knockout mice 46
both survival and clinical condition were significantly improved after zymosan
challenge if compared to the respective wildtype controls. Also, intervention
studies directed at TNF-α using either a specific antibody 47, chlorpromazine 48,
IL-10 49,50 and the alkaloid fangchinoline 51, have demonstrated mitigation of
zymosan-induced MODS. This was reflected in improved survival, a lesser
increase in organ weight, a less severe drop in body temperature and –weight,
improved pulmonary compliance and reduced hemorrhage formation in the
lungs. Although all these data suggest an important role for TNF-α in the
development of organ damage, it is unlikely to be the only mediator responsible
since interventions directed against TNF-α alone or even its complete absence
could reduce but not prevent the symptoms of zymosan-induced MODS.
THE COMPLEMENT SYSTEM
Excessive complement activation has been proposed to play a role in MODS 52.
Complement factor C5, participating in both the classical and alternative
pathway, is a potent polymorphonuclear neutrophil (PMN) chemoattractant.
PMNs are capable of producing a variety of inflammatory mediators, including
cytokines, oxygen radicals, proteases and arachidonic acid metabolites, thereby
possibly contributing to the tissue damage observed in MODS.
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Nieuwenhuijzen et al.53 injected C5 deficient mice and C5 sufficient mice with
zymosan and observed a lower mortality and a less severe decrease in body
temperature and body weight in the first, acute, phase in the C5 deficient mice.
Also, the C5 deficient mice scored better on a symptom scale of lethargy,
conjunctivitis, diarrhea and ruffled fur in this phase. However, deficiency of C5
could not prevent organ damage (assessed as the relative organ weights) in the
late, MODS-like, phase. Miller et al.54 also injected C5 deficient mice and C5
sufficient mice with zymosan, and found a lower mortality in both phases in C5-
deficient mice. However, in a follow-up study 55, the same research group did
not find significant differences in pulmonary neutrophil infiltration between the
two types of mice in the first phase, although the absence of C5 caused a
decrease in circulating neutrophil levels.
In vivo studies with complement-modulating substances have also been
performed. Ivanovska et al.56 observed that administration of complement-
inhibiting bisbenzyisoquinoline alkaloids to zymosan-treated mice yielded a
lower mortality and a lower percentage of mice with injury of liver, kidney and
spleen. The latter was assessed from the presence of macroscopically observed
fibrosis, solid accretions around these organs, foci of inflammation on renal
membranes and enlargement of the spleen.
Taken together, these studies suggest a certain involvement of complement
factors in the development of murine MODS. However, since the number of
studies is limited and the results are not unequivocal, it remains to be established
if their role is essential and causative.
OXIDANTS
The release of oxidants by activated phagocytic cells can result in severe cell
damage, most notably the peroxidation of cell membrane lipids. The lipid
peroxidation process is associated with impaired cell membrane function and
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decreased adenosine triphosphate production, eventually leading to cell lysis and
increased vascular permeability. Because of their cytotoxic effects, reactive
oxygen and nitrogen species have been implicated in the pathogenesis of MODS
33,34. Numerous studies have been undertaken to study the role of these
substances in the ZIGI model.
The occurrence of lung and liver lipid peroxidation was found to correlate well
with the triphasic illness. Lipid peroxidation is elevated in both the first 57,58 and
the third phase 58 of illness. The production capacity of superoxide (O2-) and
nitric oxide (NO) by peritoneal macrophages increases from day 7 onwards and
thus coincides with the occurrence of organ damage 59. Also, several studies
have shown the presence of nitrotyrosine, a biomarker of the reactive nitrogen
species peroxynitrite, in the course of the ZIGI model 60-63. Demling et al. 64,65
reported an increased oxidant activity in the lung and a reduced antioxidant
capacity in the liver.
Intervention studies directed at counteracting oxidant stress have also been
performed. Van Bebber et al. 66 administered a combination of superoxide
dismutase and catalase to rats treated with zymosan and found that, while lipid
peroxidation was significantly decreased, mortality and organ damage remained
unchanged. Since the rats were sacrificed 48 h after zymosan, data are limited to
the first, acute, phase. Long-term administration of hydroxyl scavengers
(mannitol, dimethylsulfoxide, dimethylthiourea) did improve neither the course
of body temperature and body weight, nor the respiratory rate, organ weights or
mortality 29. Mainous et al. 27 found that pre-treatment of rats and mice with
allopurinol or ibuprofen, which are both inhibitors of oxygen-derived free
radical production, provided protection against bacterial translocation 6 h after
zymosan injection and improved the survival rate, as measured after 7 days.
Tempol, a small molecule that permeates biological membranes and scavenges
superoxide anions and other free radicals, attenuated organ damage, as observed
histologically in lung, liver and intestine, and subsequent mortality in a study
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with rats 63. Cuzzocrea et al. 67 reported that intraperitoneal injection of N-
acetylcysteine, a glutathione precursor, prevented the development of peritonitis
and reduced peroxynitrite formation in a dose-dependent manner when given to
zymosan-shocked rats. In addition, this intervention was effective in preventing
the development of lung and intestinal injury and neutrophil infiltration. In vitro
studies have demonstrated that oxidative injury in various cell types is related in
part to DNA single strand breakage and the subsequent activation of the nuclear
enzyme poly(ADP-ribose) synthetase (PARS). 68. Massive ADP ribosilation of
nuclear proteins by PARS can result in cellular energy depletion and injury 69
and, ultimately organ damage. Several studies have shown that inhibition of
PARS prevents neutrophil recruitment and reduces microscopically visible
organ injury elicited by intraperitoneal injection of zymosan. 70-72.
An enzyme that has received special attention regarding tissue damage is
inducible nitric oxide (NO) synthase (iNOS). It is induced by cytokines and LPS
and generates NO, a reactive nitrogen species that directly and indirectly may
induce tissue damage during critical illness 73. NO is also produced by the
constitutive isoforms of nitric oxide synthase, but only in relatively small
amounts which are thought to be harmless though of great importance to normal
physiology 73. Cuzzocrea et al. have reported experiments that suggest a
causative role for NO in zymosan-induced organ damage. Administration of L-
NAME, a nonselective NOS inhibitor, attenuated zymosan-induced acute
peritonitis in rats 74,75. Also, iNOS knockout mice showed a lower mortality and
a lesser degree of microscopically visible organ damage and neutrophil
infiltration in the lungs, liver and intestine than wildtype mice 61. Also,
administration of aminoguanidine, a selective iNOS inhibitor, to wildtype mice
had similar effects. However, these beneficial effects in aminoguanidine-treated
mice and iNOS knockout mice could not be confirmed by Volman et al. 76. This
apparent discrepancy might be explained by the fact that the latter authors
examined the course of illness for at least 14 days, thus essentially investigating
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MODS after a chronic systemic inflammation. In contrast, Cuzzocrea et al.
limited their observations to the first 48 h after zymosan administration, thus
effectively studying nonseptic shock.
Taken together, it is clear that in the course of the ZIGI model there is increased
oxidant activity. Still, intervention studies aimed to suppress oxidant stress have
not demonstrated complete protection against the development of MODS. This
means that, although oxidants certainly contribute to organ damage, other
mechanisms must do so as well.
INTERVENTIONS DIRECTED AT MULTIPLE MEDIATORS
Since it appears unlikely that MODS is the result of the overexpression of a
single mediator, interventions directed at multiple mediators may be expected to
yield better results than those aimed at a single compound. Although dietary fish
oil is believed to possess anti-inflammatory effects, intervention studies with
dietary fish oil did not prevent MODS and did not reduce the expression of
TNF-α and IL-6 77,78. Cuzzocrea et al. 62 reported the effects of hyperbaric
oxygen therapy on multiple organ failure induced by zymosan  in the rat.
Although the precise molecular mechanisms remain unclear, it appeared that
hyperbaric oxygen therapy exerts potent anti-inflammatory effects on systemic
inflammation and effectively prevents the development of lung, liver and
intestinal injury. However, the experiment was ended after 72 hours, when the
degree of organ damage was only modest.
Tyrosine kinase inhibitors can reduce the formation and/or effects of TNF-α and
IL-1β, the expression of iNOS and cyclooxygenase-2 and the activation of the
transcription factor NF-κB 79,80. Dugo et al. 81 studied the effects of the tyrosine
kinase inhibitor tyrphostin AG126. This compound apparently attenuates the
severity of MODS and reduces the mortality induced by zymosan. Still, Volman
et al. did not find any beneficial effects of pentoxifylline, a substance that, at
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least in vitro, can reduce the expression of TNF-α, IL-1β and IL-6 (manuscript
in preparation).
Inhibition of NF-κB appears to be a promising approach to prevent the
development of zymosan induced MODS. Cuzzocrea et al. 82 found that
inhibition of calpain I, which is an indirect way to  prevent NF-κB activation,
results in a lesser degree of inflammatory organ damage and a lower mortality
during zymosan induced MODS in rats. In apparent contrast, recent experiments
in our laboratory failed to demonstrate any beneficial effects on morbidity and
mortality of pyrrolidine dithiocarbamate (PDTC), a non-specific NF-κB
inhibitor, in zymosan-treated mice (Volman et al., manuscript in preparation).
CONCLUSIONS AND FUTURE DIRECTIONS
Figure 2 summarizes the mechanisms which are currently thought to contribute
to the development of MODS. The ZIGI model has contributed significantly to
our understanding of its pathophysiology, especially in the areas which are
highlighted in the scheme. However, as any animal model it has its limitations.
Animal models are suitable to investigate the mechanisms of disease. They are
also necessary for the preclinical testing of potential therapeutic agents.
However, it remains difficult to extrapolate the results of such studies to clinical
practice, because, for instance, the study population in animal studies is very
homogenous (same sex and age, inbred population), whilst patient populations
usually are very heterogeneous. This does not in any way diminish the fact that
animal studies can yield valuable indications for treatment options and, if an
agent is proven successful in multiple animal models, there is a reasonable
chance that it will be effective in patients as well. In the past, many efforts have
been undertaken to identify the single mediator that causes most or all of the
trouble in generalized inflammation. It now appears that MODS is unlikely to be
the result of the overexpression of a single mediator. Intervention studies
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Figure 2. Clinical and cellular events leading to the development of MODS. The shaded areas
highlight the mechanisms where experimental studies using the ZIGI model have contributed
significantly to our knowledge.
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directed at blocking a single mediator, or a single process, have been successful
in quite a number of cases but did not result in a complete disappearance of
MODS-like symptoms. Therefore, interventions directed at multiple mediators
currently seem the most promising approach. A major problem in performing
these studies is discovering or designing agents that can block or modulate
multiple mediators in a specific way. For instance, inhibiting the expression of
multiple proinflammatory cytokines by inhibiting NF-κB seems a logical
approach, but so far very few specific NF-κB inhibitors have been available for
use in vivo. Next to this practical problem, there appears to be a great risk that
inhibition of NF-κB will have harmful side-effects, such as apoptosis of tissues
and an impaired defence to bacteria 83.
So far, studies directed at multiple mediators have been performed using
protocols that were unspecific, and the mechanisms of actions hardly
understood, which makes it difficult to draw definite conclusions from these
studies. Hopefully, far more specific interventions will become possible in the
near future. This will improve the quality of the studies and will further improve
our understanding of the underlying pathophysiology of MODS.
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ABSTRACT
Objective: To quantitate the course of specific cytokine mRNA expression in
tissues that exhibit increasing histopathological changes in time in an animal
model for the multiple organ dysfunction syndrome (MODS).
Summary Background Data: The development of treatment protocols for MODS
requires elucidation of the mechanisms and mediators involved. In order to
devise logical interventions it is necessary to collect data on cytokine expression
at tissue level during the development of MODS.
Methods: Ninety-four C57BL/6 mice were given an intraperitoneal injection of
40 µg lipopolysaccharide (LPS), followed by zymosan at a dose of 0.8 mg/g
body weight six days later (day 0). Six additional animals did not receive
zymosan and acted as controls. At several time points after zymosan injection 6
randomly assigned, zymosan-treated animals were killed and livers, lungs,
spleens and kidneys were collected. mRNA expression of  TNF-α, IL-1β, IL-6,
MIF, IL-12, IFN-γ and IL-10 was measured using a real-time reverse
transcriptase-polymerase chain reaction (RT-PCR) assay.
Results: The injection of zymosan induced an acute peritonitis, followed by an
apparent recovery. From approximately day 6 onwards, animals started to
display MODS-like symptoms. During the peritonitis phase, upregulation of
cytokine mRNA was limited. During the period of apparent recovery, cytokine
mRNA expression strongly increased, mostly reaching its maximum at day 9
when deterioration of the clinical condition had already set in. The upregulation
of TNF-α mRNA was most pronounced, especially in the lungs and liver.
Conclusions: Interventions should preferentially be targeted against multiple
cytokines and, at least in this model, there may be a treatment window well after
the initial challenge.
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INTRODUCTION
Multiple organ dysfunction syndrome (MODS) is widely considered to be the
leading cause of morbidity and mortality for patients admitted to an ICU.
MODS is not a specific disease with a well-characterized pathophysiology but
rather a common destructive pathway which may be encountered after a variety
of  serious insults like major trauma, severe bacterial infection or pancreatitis. It
is characterized by a complex and overwhelming host response that usually
occurs after massive injury or infection 1. This overwhelming host response
results in systemic inflammation, which is generally believed to be the cause of
MODS. Treatment for patients with MODS is still largely supportive. The
development of adequate treatment protocols requires elucidation of the
mechanisms and mediators involved in its pathophysiology. Lately, many efforts
have focused on the identification of endogenous mediators that participate in
the inflammatory cascade of MODS 2,3. Circulating inflammatory mediators are
relatively easy to measure, but may be a poor reflection of processes at organ
level, where the damage occurs. Since measurements at tissue sites require
invasive procedures that cannot be easily performed in humans, our group has
developed an animal model 4-6 which is acknowledged as the only one to
produce, on a consistent basis, pathological changes that mimic both the
sequence and intensity of those occurring in human MODS 7-9. After a single
insult in the form of an intraperitoneal challenge with zymosan rodents suffer an
acute, peritonitis-like phase that is followed by an apparent recovery. Thereafter,
a gradual deterioration occurs, characterized by increasing organ damage and
dysfunction 5. Previous measurements, in the circulation and on isolated
peritoneal cells, have suggested an important role in this process for pro-
inflammatory cytokines, especially TNF-α 10. Although mortality is significantly
reduced, TNF-α knockout mice still exhibit MODS-like symptoms indicating
the involvement of other mediators 6.
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In order to devise logical interventions, possibly directed at multiple cytokines,
it is necessary to collect data on their expression at tissue level during the
development of MODS. For this purpose, we have performed a comprehensive
study quantitating the course of specific cytokine mRNA expression in lung,
liver, spleen and kidney, tissues that exhibit increasing histopathological
changes in time 5.
A large number of pro-inflammatory mediators have been implicated in the
systemic inflammatory response. Specific neutralization of interleukin-(IL)1,
TNF-α, interferon-γ (IFN-γ), macrophage migration inhibiting factor (MIF), and
IL-12 has been shown to improve survival during murine endotoxemia 11. Also,
studies in critically ill patients have demonstrated that increased circulatory
levels of TNF and IL-6 are associated with organ dysfunction 12-15. During
inflammation, IL-10 is also produced. It is regarded as an anti-inflammatory
cytokine and its function is probably to mitigate the inflammatory response 16.
To gain insight into the possible role of these cytokines in its pathogenesis, we
have measured the expression of TNF-α, IL-1β, IL-6, MIF, IL-12, IFN-γ and IL-
10 mRNA in the livers, lungs, spleens and kidneys during the development of
MODS in mice.
MATERIAL AND METHODS
Animals
The experiment was performed using 100 C57BL/6 mice, 7 to 9 weeks old,
weighing 20-25 g. The animals were fed standard chow (Hope Farms RMB-H,
Woerden, The Netherlands) and acidified water ad libitum. The day/night cycle
was 12/12. Before use, the animals were allowed to acclimatize for 5 days. The
experiment was approved by the Animal Ethics Review Committee of the
University Medical Center Nijmegen.
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Zymosan-induced generalized inflammation
The zymosan-induced generalized inflammation (ZIGI) model for MODS has
been described previously 4-6. Briefly, mice were given an aseptic intraperitoneal
injection of 40 µg lipopolysaccharide (LPS) (Escherichia coli, Sigma Chemical,
St Louis, MO) dissolved in 200 µl of phosphate buffered saline (PBS), followed
six days later by zymosan administration (day 0).  Zymosan A (Sigma
Chemical) was sterilized by gamma radiation (5 kGray) and homogeneously
suspended in sterile paraffin oil (25 mg/ml) by high frequency vibration during 1
h. After sonification, the suspension was sterilized again in a waterbath at 100°C
for 80 min. All suspensions were freshly made before use. Zymosan was given
intraperitoneally in a dose of 0.8 mg/g body weight.
Experimental design
From a pool of 100 animals, mice were randomly divided into three groups.
Group 1 consisted of 84 mice that were treated with LPS and zymosan. Six
additional animals did not receive any experimental treatment and acted as
controls (group 2). To monitor the clinical course due to zymosan treatment, a
group of 10 additional mice (group 3) was treated with LPS and zymosan and
their body temperature, body weight and survival were monitored until day 17,
when surviving animals were killed.
At days 2, 5, 7, 9, 11, 13, and 15 after zymosan injection 6 randomly assigned
animals from group 1 were killed and livers, lungs, spleens and kidneys were
collected. This was also done with the surviving animals at day 17 (11 zymosan-
treated mice and the 6 control mice from group 2), when the experiment was
ended. Lung damage was assessed macroscopically, using an arbitrary lung
score: 0: no hemorrhages 1: hemorrhagic spots covering approximately 1-25%
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of the lung surface; 2: confluent hemorrhagic spots covering approximately 25-
50% of the lung surface; 3: great areas of hemorrhaging covering 50-75% of the
lung surface; 4: completely hemorrhagic lungs (75-100% of the surface covered
with hemorrhages).
Quantitative Reverse Transcriptase Polymerase Chain Reaction
After collection, organs were snap-frozen in liquid nitrogen and stored at –80°C.
Frozen organs were homogenized and total RNA was extracted with the
guanidinium thiocyanate-phenol-chloroform method according to Chomczynski
and Sacci 17. RNA concentration was determined by spectrophotometric
measurements with a GeneQuant II RNA/DNA calculator (Amersham
Pharmacia Biotech, Uppsala, Sweden). The purity of precipitated total RNA was
ascertained by 1% agarose gel electrophoresis.
Isolated RNA was used as a template for the production of first strand cDNA
using random hexamers. Relative quantification of target mRNA was performed
with a TaqMan real-time RT-polymerase chain reaction (PCR) assay on an ABI
PRISM 7700 Sequence Detector (Applied Biosystems, Foster City, CA).
Briefly, this method uses the 5’-3’ exonuclease activity of Taq polymerase to
cleave a dually labeled non-extendable TaqMan probe designed to hybridize to a
sequence between the forward and the reverse primer. The probe has a quencher
dye (6-carboxytetramethylrhodamine) on its 3’ end and a reporter dye (6-
carboxyfluorescein) at its 5’ end. Fluorescence emission of the reporter dye is
quenched by the quencher dye until nuclease degradation by Taq polymerase
during the extension phase of the PCR separates the two dyes and enables
detection of the reporter dye fluorescence. The threshold cycle (Ct) is defined as
the fractional cycle number at which the reporter fluorescence reaches 10x the
standard deviation of the baseline. Quantification of the amount of target in
unknown samples is accomplished with measurement of Ct and use of a
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standard curve to determine the starting concentration of target. Standard curves
for TNF-α, IL-1β, IL-6, MIF and IL-10 were generated using RNA from a
mouse macrophage cell line (J774-A1) that was stimulated with LPS (1 µg/ml)
for 6 h (TNF-α, IL-1β, MIF) or 4h (IL-6, IL-10), respectively. Standard curves
for IL-12 were generated using RNA for J774-A1 cells that were stimulated with
LPS (1 µg/ml) and hIFN-γ (10 ng/ml) for 9h. Standard curves for IFN-γ were
generated using RNA from murine spleen cells that were stimulated with anti-
CD3 (10 µg/ml) for 12h.
In order to correct for variations in cDNA concentration between samples, target
gene expression was normalized by dividing the starting concentration of target
by the starting concentration of constitutively expressed 18S ribosomal RNA
(endogenous control). There were differences in the expression of different
target genes in organs of untreated control mice (Table 1). Because in this study
we were interested in changes of gene expression during the course of the
animal model, the results in figures are represented as upregulations of gene
expression. Upregulation of gene expression at any time point was calculated as
the median of normalized gene expressions divided by the median of normalized
gene expressions of untreated control mice.
Oligonucleotide primers and TaqMan probes were designed with use of the
Primer Express 1.0 software (Applied Biosystems Inc). In order to avoid
amplification of genomic DNA, cDNA specific primer sets were used when
possible (TNF-α, IL-1β, IL-6, IL-12, IFN-γ and IL-10) or, when impossible
(MIF), contaminants of genomic DNA was removed from the RNA samples
using DNase I (Boehringer Mannheim) before cDNA synthesis. Primers for IL-
12 were selected using the gene sequence of the p40 subunit of IL-12. The
sequences of primers and probes are represented in table 2.
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The PCR conditions were as follows: for amplification of the target product, 25
ng of cDNA (except MIF: 2.5 ng) was added to the PCR mixture consisting of
25 µl TaqMan Mastermix (Applied Biosystems), 12.5 pmol fluorescent probe
Table 1. Constitutive gene expression of target genes in organs of untreated control mice.
  TNF-α       IL-1β         IL-6         MIF*         IL-12        IFN-γ         IL-10
Liver  30.9(2.0)   32.1(1.1)   37.9(1.2)   26.8(1.2)   38.9(1.3)   35.9(2.1)   36.7(1.1)
Lungs  30.7(2.4)   29.6(2.7)   35.3(2.3)   33.3(2.1)   32.9(1.0)   36.3(2.4)   36.9(1.4)
Spleen  28.5(0.2)   26.5(0.7)   35.3(1.2)   28.8(0.7)   29.4(0.9)   31.8(0.3)   32.1(0.7)
Kidneys 36.2(2.6)   32.5(3.1)   40.0(0.1)   23.7(0.7)   35.5(1.9)   37.5(2.1)   39.8(0.3)
Data represent average Ct values and standard deviations between brackets (n=6).
* for MIF, 10 times less cDNA (2.5 ng) was used for the PCR reaction than for other
 cytokines (25 ng)
Table 2. Sequences (5’-3’) of primers and probes used in PCR reactions
target forward primer reverse primer probe
TNF-α CCCAGACCCTCACACTCAGATC CCTCCACTTGGTTTGCT CGAGTGACAAGCCTGTAGCCCACGT
IL-1β GGACAGAATATCAACCAACAAGTGAT ATTACACAGGACAGGTATAGATTCTTTCCT AACGACAAAATACCTGTGGCCTTGGGC
IL-6 TGTATGAACAACGATGATGCACTT GGTACTCCAGAAGACCAGAGGAAAT TTTGGTAGCATCCATCAT*
MIF GCAAGCCCGCACAGTACA CGTTCGTGCCGCTAAAAGTC CTGGTCCGGGACCACGTGCACT
IL-12 TCAACATCAAGAGCAGTAGCAGTTC AGTCCCTTTGGTCCAGTGTGA CCATTCCACATGTCACTGCCCGAGA
IFN-γ TGGAGGAACTGGCAAAAGGAT GCCTGATTGTCTTTCAAGACTTCAA TGACATGAAAATCCTGCAGAGCCAGATTATC
IL-10 AGTGGAGCAGGTGAAGAGTGATT TCATGTATGCTTCTATGCAGTTGATG CAAATTCATTCATGGCCTTGTAGACACCTTG
* Taqman minor groove binder (MGB)-probe
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(Applied Biosystems) and 15 pmol of each primer in a final volume of 50 µl.
For amplification of the 18S rRNA product, the PCR mixture consisted of 25 µl
TaqMan Mastermix and 2.5 µl of pre-developed TaqMan 18S rRNA control kit
(Applied Biosystems). Again, the final volume was 50 µl. Thermal cycling
conditions were 2 min at 50°C and 10 min of initial denaturation at 95°C to
activate Taq Gold polymerase, followed by 40 cycles of 2-step PCR consisting
of 15 s at 95°C and 1 min at 60°C.
RESULTS
Clinical Course
Survival, body temperature and body weight of mice in group 3 are represented
in figure 1. The clinical course of the animal model was similar as described
previously 5,6. Briefly, after the injection of LPS the animals became ill for 1
day, but by the time they received zymosan (day 0) the mice had recovered
completely. The injection of zymosan induced an acute peritonitis rendering all
animals very ill during the first 2 days, as reflected by a ruffled fur, diarrhea,
lethargic behavior, and a decrease in body weight and temperature. During the
second phase of the illness (days 3-5), the condition of the surviving animals
appeared to return to normal, with an increase in body weight and temperature.
From approximately day 6 onward, mice entered the third -MODS-like- phase,
indicated by lethargic behavior, breathing difficulties, weight loss, and a
decrease in body temperature. The survival curve of mice in group 1 was similar
to that of mice in group 3 (Figure 2A). Lung scores of mice in group 1 that were
killed at different time points indicate progressive organ damage from day 5
onwards (Figure 2B).
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Figure 1. Clinical course after zymosan administration. A group of 10 animals (group 3) was
followed to monitor survival (A),  body temperature (B) and body weight (C). The latter are
depicted as average + SD.
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Figure 2. Survival and development of lung damage after zymosan administration. A: Kaplan-
Meier survival curve in group 1 (n=84 at day 0), which was used for cytokine mRNA
quantitation; B): Lung score for mice in groups 1 and 2 (controls). Bars represent average
values (+ SD, n=6 for controls and days 2-15 and n=11  for day 17).
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TNF-α  mRNA expression
TNF-α mRNA was strongly upregulated in all organs, except for the spleen
(Figure 3A). Figure 3 gives, for reasons of clarity, median values only. In order
to demonstrate the degree of variation observed between animals, the expression
of TNF-α (and IL-1β) mRNA in the liver of all individual animals is illustrated
in Figure 4. In the liver, TNF-α message started to increase strongly between
days 5 and 7, and peaked around day 9 with a mRNA expression that was 85
times higher than in control animals. After day 9, the expression of TNF-α
message in the liver gradually decreased, but remained high until the end of the
experiment. In the lungs, the increase in TNF-α message was even higher than
in the liver and significant upregulation was observed earlier: at day 2, the
increase in TNF-α message was already 16-fold. At day 9, there was a transient
and extremely high peak of TNF-α message (237 times the level of controls),
but the expression was reduced quickly again over the next 2 days , whereafter
the upregulation slowly decreased further. However, it was still substantial at
day 17. The upregulation of TNF-α message at day 2 was higher in the kidneys
than in the other organs. It peaked again at day 11 and gradually declined
afterwards.
IL-1β  mRNA expression
The expression of IL-1β message was also substantially increased in all organs,
again with exception of the spleen (Figure 3B). In the liver, a strong  increase
started from day 5 onwards, reaching a peak at day 9, when the expression of
IL-1β mRNA was 25 times the level of controls. Upregulation decreased
significantly only after day 15 (Figures 3B and 4). In contrast, there was only a
limited increase in IL-1β message in the lungs, showing a maximum at day 5. In
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the kidneys, however, there was already a remarkable upregulation of  IL-1β
mRNA at day 2, which reached a peak at day 11 (24-fold).
IL-6 mRNA expression
Significant upregulation of IL-6 mRNA appeared to be limited to liver and
kidneys. The expression of IL-6 mRNA in the liver started to increase after day
2 and reached a maximum at days 9 to 11, when the expression was around 15
times the level of controls (Figure 3C); thereafter, the level of mRNA quickly
decreased to values approximately 3 times the level of controls. The expression
of IL-6 message in the kidneys was upregulated 12-fold at day 2, after which it
dropped rapidly.
MIF mRNA expression
In general, the expression of MIF mRNA in the collected organs was very high.
However, MIF mRNA was also abundantly expressed in the organs of control
animals, as reflected by low Ct values of organs of control mice (Table 1).
Therefore, there was no substantial upregulation of MIF mRNA in any organ at
any time point (Figure 5A).
IL-12 mRNA expression
The upregulation of IL-12 message in the liver was high: after day 5, the level of
mRNA quickly increased to 44 times the level in control animals at day 9
(Figure 5B). Thereafter it slowly subsided but remained significantly elevated
until day 17. In neither lungs nor spleen, an increase of IL-12 message was
observed. In fact, in the spleen there appeared to be a substantial downregulation
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of IL-12 message. In the kidneys, IL-12 mRNA did not change until day 11,
when there was a 9-fold increase which slowly disappeared with time.
IFN-γ  mRNA expression
There was an increased expression of IFN-γ mRNA  in all organs except for the
spleen (Figure 5C). In the liver, the mRNA level sharply increased after day 5,
and remained high until day 15. In the lungs, the presence of  IFN-γ mRNA
gradually increased until day 11, where levels were 24-fold upregulated. In the
kidneys, the IFN-γ mRNA expression increased from a 6-fold downregulation at
day 2 to a 12-fold upregulation at day 7. After that, the level of mRNA
fluctuated around 3 times the levels of controls.
IL-10 mRNA expression
In most organs, IL-10 mRNA expression was substantially elevated (Figure 5D).
Upregulation was most explicit in the kidneys. However, here the constitutive
expression in control animals was extremely low. In the liver, the level of
upregulation increased from 4-fold at day 2 to 40-fold at day 9. After that, the
IL-10 mRNA expression decreased again. In the lungs, the expression of IL-10
mRNA was also upregulated, but it strongly fluctuated with time. It was
maximal at day 15, when the expression was 35 times the level of controls. The
IL-10 mRNA expression in the spleen was not much higher than in control
animals.
DISCUSSION
The development of MODS in this animal model is accompanied by massive
upregulation of the mRNAs for multiple pro-inflammatory cytokines in several
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Figure 3. Upregulation of TNF-α (A), IL-1β (B), IL-6 (C) mRNA. The degree of upregulation
was calculated for each animal as the mRNA expression at any time point in relation to the
median mRNA expression in control mice. Data are represented as medians. +liver, ■lungs,
∆spleen, ×kidneys, n=6 per organ per time point.
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Figure 4. Cytokine mRNA expression in the liver. Individual values of mRNA for TNF-α (●)
and IL-1β (○), quantitated by a real-time RT-PCR, in livers from untreated control mice and
zymosan-treated animals.
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organs. In the early days after zymosan administration, during the acute
peritonitis phase, upregulation appears to be limited. During the period of
apparent recovery, cytokine mRNA expression strongly increases, mostly
reaching its maximum at day 9 when deterioration of the clinical condition has
already set in.
The cytokines that were examined in this study have all been related to systemic
inflammation 2 and could therefore play a role in the pathophysiology of MODS.
Of the cytokines examined, the upregulation of TNF-α mRNA is most
pronounced, especially in the lungs and liver. The rise in TNF-α mRNA in the
lungs precedes that in the liver, which agrees with the general observation that
the lungs are the first organs affected during the development of MODS.
These findings, which indicate a major role for TNF-α in the pathophysiology,
extend and support data previously reported. We have found elevated levels of
TNF-α in the circulation during the third phase as well as a significantly
enhanced lipopolysaccharide(LPS)-stimulated production of TNF-α by
peritoneal cells, predominantly macrophages, over the entire experimental
period 10. Moreover, in TNF-α-lymphotoxin-α knockout (TNF/LT-/-) mice both
survival and clinical condition were improved after zymosan challenge if
compared to their wildtype controls 18. Similar results have been reported by
others for TNF receptor p55 knockout mice 19. Although all these data suggest
an important role for TNF-α in the development of organ damage, it is unlikely
to be the only mediator responsible since TNF/LT-/- mice still develop organ
damage 18. Also, intervention studies directed at TNF-α using a specific
antibody, chlorpromazine and IL-10, respectively, could mitigate but not prevent
the symptoms of zymosan-induced MODS 20-22.
The results of the current study underscore a role for other cytokines. In several
organs the mRNA expression of the pro-inflammatory cytokines IL-1β, IL-6,
IL-12 and IFN-γ was elevated at certain time points, although the degree of
upregulation was not as high as for TNF-α. Plasma concentrations of IL-1β and
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IL-6 are consistent predictors of outcome in patients with the adult respiratory
distress syndrome (ARDS) 23. Since TNF-α induces the synthesis of IL-1 and
IL-6 in many cell types, the upregulation of these two cytokines in this study
might be explained by the upregulation of TNF-α. However, this effect cannot
occur in TNF knockout mice, and these mice still develop organ damage.
Cuzzocrea et al. 24 found an improved clinical condition in a non-septic shock
model using either IL-6 knockout mice or antibodies against IL-6, suggesting a
major role of IL-6 in systemic inflammation. Also, concentrations of circulating
IL-6 have been found to parallel disease severity in septic patients 25. However,
IL-6 is fairly well tolerated when given to dogs 26, making it unlikely that IL-6 is
the driving force behind the physiology of inflammatory diseases.
IL-12 and IFN-γ are produced during sepsis and endotoxemia 27-29, and are
necessary for an adequate immune response against invading microorganisms
30,31. However, IL-12 and IFN-γ may also play a detrimental role in a systemic
inflammatory response. Administration of anti-IL-12 antibodies in a murine
model of endotoxemia resulted in a lower mortality 32. Also, Lauw et al. 33 found
that a single injection of IL-12 caused a delayed and sustained activation of
multiple inflammatory pathways in the absence of detectable plasma
concentrations of TNF and IL-1β, suggesting that these pathways are
independent of these two potent proinflammatory cytokines. Since IL-12
induces IFN-γ production by T cells and natural killer cells 30, it cannot be ruled
out that at least a part of the observed effects in in these studies may have
contributed to IFN-γ.
Because in this study mRNAs of multiple cytokines are upregulated, blocking
multiple cytokines simultaneously is likely to give the best results in
intervention studies. Since the expression of TNF-α, IL-1β, IL-6 and IL-12 is
nuclear factor kappa B (NFκB) mediated 34, intervention studies with NFκB
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inhibitors seem an obvious way to do. Unfortunately, there is still no specific
NFκB inhibitor available that can be used in vivo.
In this model, we did not find a high level of upregulation of MIF mRNA in any
organ. The murine genome contains several pseudogenes for MIF. It is,
however, very unlikely that these can confound our quantitative PCR, since
transcription of MIF pseudogenes has never been observed 35. Our finding of
limited upregulation of MIF message does, however, not necessarily mean that
MIF does not play an important role in the onset of MODS in mice. The
expression of MIF mRNA was very high in most organs, but since MIF mRNA
was constitutively expressed, this did not result in a high level of upregulation.
Monocytes/macrophages have been shown to contain large quantities of
preformed MIF that is released after several stimuli, such as LPS or TNF-α 36.
Therefore, MIF mRNA production might not be a good predictor of actual MIF
activity.
In the liver and lungs, but especially in the kidneys we found a high level of
upregulation of IL-10. This cytokine is regarded as an anti-inflammatory
cytokine because of its inhibitory effect on the production of IL-1α, IL-1β, IL-6,
IL-8, TNF-α and IFN-γ 37. The release of IL-10 by macrophages in response to
LPS is regarded as a natural anti-inflammatory response mitigating cytokine
production 16. Also, IL-10 is produced in patients with circulatory shock from
septic and nonseptic origin, and its production correlates positively with the
intensity of the inflammatory response 38. It is conceivable that also in this
model for MODS, IL-10 is produced to mitigate the severe inflammatory
response. The extremely elevated IL-10 mRNA levels observed in the kidneys
could possibly provide an explanation for the fact that the organ damage in the
kidneys in this model is limited compared to liver, lungs and spleen. To our
knowledge, there are no related pathological conditions in which IL-10 is
abundantly expressed in kidneys.
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The liver was the organ in which the most cytokine mRNA upregulation could
be seen. Except for MIF, all examined cytokines were upregulated more than
tenfold at any time point in the liver, whereas in the lungs this was only the case
for TNF-α, IFN-γ, and IL-10 and in the spleen for no cytokine at all. In the
kidneys, however, all examined cytokines except MIF and IL-12 were
upregulated more than tenfold at any time point. This is not completely in
agreement with the occurrence of organ damage, because the damage in the
lungs is the most severe, whereas the kidneys are relatively unaffected. If,
however, the occurrence of organ damage is mainly mediated by TNF-α, this
would provide an explanation for the severe lung damage observed in this
model, since the upregulation of TNF-α was extremely high in the lungs.
The current data pertain to cytokine message and not to actual levels of cytokine
protein. It is generally believed that a strongly increased presence of  mRNA,
such as demonstrated here, will translate into increased levels of the biologically
active protein. However, as with all studies on gene expression, one should
realize that a discrepancy between protein production and mRNA levels remains
possible. Still, with the techniques available it is extremely difficult to quantitate
tissue levels of mediator proteins such as cytokines.
The experimental procedures used in this study do not allow the identification of
the cell types responsible for the increased cytokine mRNA expression in the
organs. Previous studies in our laboratory 5,18 have demonstrated an influx of
inflammatory cells in the various tissues during the development of organ
damage. For instance, there is an influx of macrophages and neutrophils in the
liver, there are accumulations of lymphocytes, plasma cells and neutrophils in
the lungs, and accumulations of macrophages in the capsule of the spleen.
Although it seems likely that these inflammatory cells are responsible for the
increased presence of cytokine mRNA, we cannot rule out that resident cells
also exhibit an increased gene expression.
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The overall view that arises from the current data is that the upregulation of
mRNA for a number of pro-inflammatory mediators becomes most explicit from
5 days after the zymosan challenge onwards, coinciding in time with the
development of microscopic organ damage as reported before 5. This finding is
of particular interest with respect to future intevention studies. Since cytokine
mRNA levels only peak after the onset of the MODS-like phase and
upregulation appears limited in the early days, there seems to be ample room for
interventions after the initial challenge, perhaps even extending well into the
second – recovery – phase of the model. Obviously, one should be exceedingly
careful to extrapolate the results to the clinical situation. Even so, if we
hypothesize that the systemic inflammation, which is believed to be the driving
force for the development of MODS in patients, comprises a similar pattern of
cytokine mRNA upregulation, this would offer a window of opportunity for
intervention well after the original insult. Next to the conclusion that most likely
multiple cytokines should be targeted, this appears a promising finding which
needs to be explored further.
ACKNOWLEDGMENT
We thank Louis van der Locht (Department of Hematology) for his expert
technical assistance with the real-time PCR procedures.
References
1. Seely AJ, Christou NV. Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit
Care Med 2000; 28:2193-2200.
2. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001;
29:S99-106.
3. Papathanassoglou ED, Moynihan JA, Ackerman MH. Does programmed cell death (apoptosis) play a role in the development
of multiple organ dysfunction in critically ill patients? a review and a theoretical framework. Crit Care Med 2000; 28:537-549.
4. Goris RJ, Boekholtz WK, van Bebber IP et al. Multiple-organ failure and sepsis without bacteria. An experimental model.
Arch Surg 1986; 121:897-901.
5. Jansen MJ, Hendriks T, Verhofstad AA et al. Gradual development of organ damage in the murine zymosan-induced multiple
organ dysfunction syndrome. Shock 1997; 8:261-267.
57
6. Volman TJH, Goris RJ, van der Jagt M et al. Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice
is not mediated by inducible nitric oxide synthase. Crit Care Med 2002; 30:1553-1559.
7. Demling R, Lalonde C, Youn YK et al. Lung oxidant changes after zymosan peritonitis: relationship between physiologic and
biochemical changes. Am Rev Respir Dis 1992; 146:1272-1278.
8. Shayevitz JR, Miller C, Johnson KJ et al. Multiple organ dysfunction syndrome: end organ and systemic inflammatory
response in a mouse model of nonseptic origin. Shock 1995; 4:389-396.
9. Cuzzocrea S, McDonald MC, Mazzon E et al. Beneficial effects of tempol, a membrane-permeable radical scavenger, on the
multiple organ failure induced by zymosan in the rat. Crit Care Med 2001; 29:102-111.
10. Jansen MJ, Hendriks T, Vogels MT et al. Inflammatory cytokines in an experimental model for the multiple organ dysfunction
syndrome. Crit Care Med 1996; 24:1196-1202.
11. Marshall JC, Creery D. Pre-clinical models of sepsis. Sepsis 1998; 2:187-197.
12. Roumen RM, Hendriks T, Ven-Jongekrijg J et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic
shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann
Surg 1993; 218:769-776.
13. Borrelli E, Roux-Lombard P, Grau GE et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant
vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 1996; 24:392-397.
14. Panacek EA, Kaul M. IL-6 as a marker of excessive TNF-alfa activity in sepsis. Sepsis 1999; 3:65-73.
15. Geppert A, Steiner A, Zorn G et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma
levels of interleukin-6. Crit Care Med 2002; 30:1987-1994.
16. Marchant A, Bruyns C, Vandenabeele P et al. Interleukin-10 controls interferon-gamma and tumor necrosis factor production
during experimental endotoxemia. Eur J Immunol 1994; 24:1167-1171.
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform
extraction. Anal Biochem 1987; 162:156-159.
18. Volman TJH, Hendriks T, Verhofstad AA et al. Improved survival of TNF-deficient mice during the zymosan-induced
multiple organ dysfunction syndrome. Shock 2002; 17:468-472.
19. Burdon D, Tiedje T, Pfeffer K et al. The role of tumor necrosis factor in the development of multiple organ failure in a murine
model. Crit Care Med 2000; 28:1962-1967.
20. Jansen MJ, Hendriks T, Hermsen R et al. A monoclonal antibody against tumour necrosis factor-alpha improves survival in
experimental multiple organ dysfunction syndrome. Cytokine 1998; 10:904-910.
21. Jansen MJ, Hendriks T, Knapen MF et al. Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates
experimental multiple organ dysfunction syndrome in mice. Crit Care Med 1998; 26:1244-1250.
22. Jansen MJ, Hendriks T, de Man BM et al. Interleukin 10 mitigates the development of the zymosan-induced multiple organ
dysfunction syndrome in mice. Cytokine 1999; 11:713-721.
23. Meduri GU, Headley S, Kohler G et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS.
Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995; 107:1062-1073.
24. Cuzzocrea S, de Sarro G, Costantino G et al. Role of interleukin-6 in a non-septic shock model induced by zymosan. Eur
Cytokine Netw 1999; 10:191-203.
25. Damas P, Ledoux D, Nys M et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg
1992; 215:356-362.
26. Preiser JC, Schmartz D, Van der Linden P et al. Interleukin-6 administration has no acute hemodynamic or hematologic effect
in the dog. Cytokine 1991; 3:1-4.
27. Calandra T, Baumgartner JD, Grau GE et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-
alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect
Dis 1990; 161:982-987.
28. Heinzel FP, Rerko RM, Ling P et al. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma
interferon. Infect Immun 1994; 62:4244-4249.
58
29. Hazelzet JA, Kornelisse RF, Pouw-Kraan TC et al. Interleukin 12 levels during the initial phase of septic shock with purpura in
children: relation to severity of disease. Cytokine 1997; 9:711-716.
30. Curfs JH, Meis JF, Hoogkamp Korstanje JA. A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol
Rev 1997; 10:742-780.
31. Zantl N, Uebe A, Neumann B et al. Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel
murine model of abdominal sepsis. Infect Immun 1998; 66:2300-2309.
32. Wysocka M, Kubin M, Vieira LQ et al. Interleukin-12 is required for interferon-gamma production and lethality in
lipopolysaccharide-induced shock in mice. Eur J Immunol 1995; 25:672-676.
33. Lauw FN, Dekkers PE, te-Velde AA et al. Interleukin-12 induces sustained activation of multiple host inflammatory mediator
systems in chimpanzees. J Infect Dis 1999; 179:646-652.
34. Sun Z, Andersson R. NF-kappaB activation and inhibition: a review. Shock 2002; 18:99-106.
35. Kozak CA, Adamson MC, Buckler CE et al. Genomic cloning of mouse MIF (macrophage inhibitory factor) and genetic
mapping of the human and mouse expressed gene and nine mouse pseudogenes. Genomics 1995; 27:405-411.
36. Calandra T, Bernhagen J, Mitchell RA et al. The macrophage is an important and previously unrecognized source of
macrophage migration inhibitory factor. J Exp Med 1994; 179:1895-1902.
37. Smith EM, Cadet P, Stefano GB et al. IL-10 as a mediator in the HPA axis and brain. J Neuroimmunol 1999; 100:140-148.
38. Marchant A, Alegre ML, Hakim A et al. Clinical and biological significance of interleukin-10 plasma levels in patients with
septic shock. J Clin Immunol 1995; 15:266-273.
59
4
Improved survival of TNF-deficient mice
during the zymosan-induced multiple organ
dysfunction syndrome.
Volman,TJH; Hendriks,T; Verhofstad,AAJ; Kullberg,BJ;
Goris,RJA
Shock. 2002 Jun; 17(6): 468-72
60
ABSTRACT
The purpose of the study was to investigate the course of the zymosan-induced
multiple organ dysfunction syndrome (MODS) in the absence of  Tumor
Necrosis Factor (TNF) in a murine model. 36 TNF-α/LT-α knockout (-/-) mice
and 36 wildtype (+/+) mice received 40 µg LPS ip, followed by zymosan at a
dose of 1 mg/g body weight 6 days later (day 0). Animals were monitored daily
for body weight and temperature and clinical symptoms. At day 22, most of the
surviving  mice were killed to examine organ weight and histology. A small
number of animals was followed until day 48. In all animals zymosan induced
an acute sterile peritonitis phase followed by an apparent recovery. From day 8
onwards the TNF/LT+/+ mice entered a third - MODS-like - phase,
characterized by loss of body weight, decreased body temperature and
significant mortality. At day 22, survival in the TNF/LT-/- mice (92%) was
significantly (P=0.01) higher than in the TNF/LT+/+ mice (60%). In addition,
average body temperature and average relative (vs. weight at day 0) body weight
were higher in the TNF/LT-/- mice than in the TNF/LT+/+ mice (35.9°C and
100% versus 33.3°C and 84%, respectively). However, at this time point,
surviving animals from both groups showed similar and significant organ
damage, indicated by an increase in absolute and relative (vs body weight)
weight of lung, spleen and liver (liver only in the TNF/LT-/- mice). Moreover,
histopathological examination of organs from the surviving animals showed a
similar degree of microscopic damage in both groups. Interestingly, besides
mononuclear cells, inflammatory infiltrates in lungs and livers of TNF/LT+/+
but not of TNF-/- mice contained neutrophils. In conclusion, TNF-deficient mice
exhibit significantly improved morbidity and mortality during zymosan-induced
MODS. However, the absence of TNF does not completely protect against
MODS in this murine model.
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INTRODUCTION
Multiple organ dysfunction syndrome (MODS) is characterized by serious
inflammation that leads to deterioration of several organ functions, starting
mostly with lung failure and followed by failure of the liver, gut and kidneys 1. It
is the principal cause of death on the intensive care unit in patients suffering
from multiple trauma, shock, peritonitis, or pancreatitis 1,2.
Despite our much increased understanding of infection, sepsis, trauma and cell
and organ injury over the last decades, the exact pathophysiology of MODS
remains to be elucidated.  The syndrome involves organs that are not necessarily
directly involved in the primary disease 1. Furthermore, between the primary
disease or insult and the development of MODS lies a period of days to weeks.
In the mid-1980s it was suggested that MODS might result not from infection
per se, but from an uncontrolled, systemic inflammatory response 3. This
hypothesis is now generally accepted 2,4-7. Since its initial description in 1973 8,
no substantial improvement of treatment strategy has occurred. Once MODS
develops, the morbidity and mortality remain high, so prevention is still the best
solution for MODS. Aggressive support of normal organ function is currently
the best way to  prevent MODS 9.
Research of MODS in humans is hampered by the fact that the patients at risk
for MODS do not constitute a very homogenous group. Also, the examination of
the mechanisms behind MODS requires invasive procedures, which cannot be
easily performed on humans. In our laboratory, an animal model for MODS has
been developed 10,11 and since then it has been adopted by others, sometimes in
modified versions 12-14. In this model, intraperitoneal administration of zymosan
in a paraffin oil suspension leads to a three phasic illness, consisting of an acute
sterile peritonitis, followed by a period of apparent recovery and, finally, the
development of MODS-like symptoms, characterized by progressive damage in
multiple organs 11.
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Since MODS is now believed to be the result of a generalized inflammation,
much attention has focused on the role of pro-inflammatory mediators in its
pathophysiology 15. TNF-α and lymphotoxin(LT)-α are pro-inflammatory
cytokines and members of the TNF-family. They both bind to the same
receptors, induce overlapping intracellular pathways and lead to similar
biological effects 16. MODS usually occurs in patients with sepsis, and it is well-
established that TNF-activity is elevated during sepsis 17. Previous experiments
18 in our laboratory have shown that plasma TNF-α levels were increased during
the first 24 h after administration of zymosan in mice, followed by a prominent
peak from day 8 onwards. Moreover, subsequent experiments revealed that
interventions directed at TNF could mitigate the symptoms of zymosan-induced
MODS, indicating a critical role for TNF in the pathophysiology. These
interventions consisted of the administration of the anti-inflammatory cytokine
IL-10 19, a monoclonal antibody against TNF-α 20, or chlorpromazine 21. These
findings raise the question whether zymosan-induced MODS can develop in the
absence of TNF. Because both TNF and LT interact with the same membrane
receptors and have similar effects, the absence of one of these cytokines may be
partly compensated by actions of the other one. To exclude the possible
redundant effects of the two cytokines, we investigated the course of zymosan
induced generalized inflammation in TNF-α/LT-α double knockout mice.
MATERIAL & METHODS
Animals
Experiments were performed with TNF-α and LT-α double knockout (TNF/LT
-/-) mice and wildtype (TNF/LT+/+) mice, 7 to 9 weeks old, weighing 20-25 g.
The TNF/LT-/- mice were characterized elsewhere 22. The animals were fed
standard chow (Hope Farms RMB-H, Woerden, The Netherlands) and acidified
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water ad libitum. The day/night cycle was 12/12. Before use, the animals were
allowed to acclimatize for 5 days. The experiments were approved by the
Animal Ethics Review Committee of the University Medical Centre Nijmegen,
in adherence to the NIH guidelines for the use of experimental animals.
Zymosan-induced generalized inflammation
The zymosan-induced generalized inflammation (ZIGI) model for MODS has
been described previously 11. In order to improve reproducibility and to limit
mortality in the first phase, a small modification to the initial model was
introduced, consisting of an aseptic intraperitoneal injection of 40 µg LPS
(E.coli, Sigma, St. Louis, MO) dissolved in 200 µl PBS,  six days prior to
zymosan administration.  Zymosan A (Sigma, St. Louis, MO) was sterilized by
gamma radiation (5 kGray) and homogeneously suspended in sterile paraffin oil
(25 mg/ml) by high frequency vibration during 1 h. After sonification, the
suspension was sterilized again in a waterbath at 100°C for 80 min. All
suspensions were freshly made before use. Zymosan was given intraperitoneally
in a dose of 1 mg/g body weight.
Experimental design
Two experiments were performed. In experiment 1, 24 TNF/LT-/- mice and 25
TNF/LT+/+ mice were treated with LPS and zymosan. Six additional animals
(three of each group) received neither zymosan nor LPS and acted as controls.
Survival, body weight and body temperature were monitored. At day 22, 10
TNF/LT-/- mice and 5 TNF/LT+/+ mice were killed by cervical dislocation and
the lungs, liver, and spleen were collected and weighed. Lung damage was
assessed macroscopically, using an arbitrary lung score: 0: no hemorrhages 1:
hemorrhagic spots covering approximately 1-25% of the lung surface; 2:
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confluent hemorrhagic spots covering approximately 25-50% of the lung
surface; 3: great areas of hemorrhaging visible covering 50-75% of the lung
surface; 4: completely hemorrhagic lungs (75-100% of the surface covered with
hemorrhages). In order to ensure that the TNF/LT-/- would not display a high
mortality later on, the surviving animals were followed until  day 48, when all
animals were killed.
In experiment 2, 12 TNF/LT-/- mice and 11 TNF/LT+/+ mice were treated with
LPS and zymosan and again survival, body weight and body temperature were
monitored. At day 22, the surviving animals were killed and the lungs, liver, and
spleen were harvested for histology. The organs were fixed for 24 hours in
phosphate buffered 4% formaldehyde, dehydrated, and embedded in paraffin.
Sections of 4µm in thickness were stained with hematoxylin-eosin.
Statistical analysis
Statistical significance of differences in mortality between experimental groups
was determined using a two-sided Fisher’s exact test. Statistical significance of
differences in body temperature, relative body weight, relative organ weights
and lung scores were determined using a two-sided Mann-Whitney U test. P-
values smaller than 0.05 were considered significant.
RESULTS
Clinical  condition
After the injection of LPS on day –6, the animals became ill for one day,
indicated by a transient loss in body weight. By the time they received zymosan
(day 0), the animals had recovered completely. If mice received LPS only and
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no zymosan, their clinical course ran equal to that observed for the control group
which received neither LPS nor zymosan (results not shown).
The injection of zymosan induced an acute sterile peritonitis rendering all
animals very ill during the first two days, reflected by a ruffled fur, diarrhea,
lethargic behavior and a decrease in body weight. The TNF/LT+/+ mice but not
the TNF/LT-/- mice also displayed a transient loss of body temperature. During
the second phase of the illness (day 3 to 5) the condition of the surviving
animals appeared to return to normal, reflected by the display of natural
curiosity, grooming, a smooth fur, and disappearance of diarrhea. Body
temperature was restored and animals gained weight again. From day 6
onwards, animals became ill again, indicated by lethargic behavior, breathing
difficulties, weight loss and a decrease in body temperature. Weight loss and
decrease in body temperature were less severe in the TNF/LT-/- mice (Figure 1).
On day 22, the average body temperature of the surviving TNF/LT+/+ mice was
33.3±3.1˚C. For TNF/LT-/- mice this was 35.9±1.0˚C (P=0.06).  The average
relative (vs. weight at day 0) body weight of surviving TNF/LT+/+ mice was
85±18.9% versus 100±10.2% for the TNF/LT-/- mice (P=0.01).
In the second experiment, performed for histological analysis of the organs, the
clinical course of the illness was similar to the first experiment (data not shown).
Survival
The TNF/LT+/+ mice showed a mortality of 8% during the first phase after
zymosan administration. Although the TNF/LT-/- mice also became ill, none
died in this early phase. During the recovery phase, there was no mortality in
both groups. In the third -MODS-like- phase, the survival of the TNF/LT-/- mice
remained high: at day 22 it was 92%, which was significantly (P=0.02) higher
than the 60% survival of the TNF/LT+/+ mice (Figure 2).
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Figure 1. Body temperature (A) and relative body weight (B) of surviving TNF/LT-/-(▲,
n=22), TNF/LT+/+ (■, n=15) and control mice (●, n=6). Data are presented as mean and
SD. Relative body weight was calculated as (body weight/body weight at day 0) * 100%.
Relative body weight was significantly different between the TNF/LT-/- and the TNF/LT+/+
group at day 22, the difference in body temperature almost reached significance (body
temperature: P=0.06, relative body weight: P=0.01 by Mann-Whitney U test).
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Figure 2. Survival of TNF/LT-/- (▲, n=24 at day 0) and TNF/LT+/+ (■, n=25 at day 0) mice
after administration of zymosan. At day 22, survival was significantly better in the TNF/LT-/-
mice (P=0.02 by Fisher’s exact test).
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12 TNF/LT-/- mice and 10 TNF/LT+/+ mice were followed until day 48, in
order to rule out the possibility that the TNF/LT-/- mice would display a high
mortality after day 22. This was not the case: 2 out of 12 surviving TNF/LT-/-
mice died between day 22 and day 48. For the TNF/LT+/+ mice this number
was 3 out of 10.
In the second experiment, performed for histological analysis of the organs,
survival at day 22 was 91% in the TNF/LT-/- mice and 30% in the TNF/LT+/+
mice. (These data were not included in figure 2.)
Organ weights and lung scores
To correct for differences in body weight between animals, organ weights are
expressed as a percentage of total body weight (relative organ weight, figure 3).
On day 22, relative lung weight was elevated in both TNF/LT-/- (P=0.01) and
TNF/LT+/+ (P=0.04) mice, as compared to untreated control animals (TNF/LT
-/- mice: 2.8±0.6%, TNF/LT+/+ mice: 3.2±0.9% and controls: 0.4±0.1%).
However, there was no difference between both experimental groups. The
average relative liver weight was higher in the TNF/LT-/- mice (8.6±2.0%) than
in the TNF/LT+/+ mice (4.2±1.0%; P=0.00) and the controls (4.6±0.2%;
P=0.01). Average spleen weights of both TNF/LT-/- (2.1±0.8%) and
TNF/LT+/+ (1.2±0.4%) mice were higher (P=0.01 and 0.04, respectively) than
controls (0.3±0.0%). Spleen weights of TNF/LT-/- mice were even higher than
those of TNF/LT+/+ mice (P=0.03).
Macroscopic lung scores were not significantly different between TNF/LT-/-
and TNF/LT+/+ mice (Figure 4).
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Histopathology
Twenty-two days after the injection of zymosan, surviving TNF/LT-/- and
TNF/LT+/+ mice both show a similar degree of histopathological abnormalities
in the lungs, the liver and the spleen, although there was variation between
animals.  The lungs showed hemorrhagic areas where the alveoli had
disappeared to a large extent (atelectasis).  In other parts the alveoli were empty
but dilated. Around the bronchi and arterioles accumulations of lymphocytes
and plasma cells were seen (Figure 5A and 5B). It was remarkable that that in
TNF/LT+/+ mice, these accumulations also contained neutrophils, whereas in
TNF/LT-/- mice almost no neutrophils could be seen. In the liver, blood vessels
were surrounded by a mononuclear infiltrate. Focal accumulations of
mononuclear cells were seen all over the liver. In contrast to TNF/LT-/- mice,
livers of TNF/LT+/+ mice also contained accumulations of neutrophils (Figure
5C and 5D). The capsule of the spleen was thickened, due to accumulations of
macrophages containing phagocytosed material. The white pulp was depleted of
lymphocytes, which resulted in the disappearance of the distinct borders
between white and red pulp. The red pulp contained numerous plasma cells
(Figure 5E and 5F).
DISCUSSION
In the present study, TNF/LT-/- mice exhibited a higher survival rate and better
clinical condition than the TNF/LT+/+ mice. The difference in survival was
most pronounced in the third phase of the model, when the MODS-like
symptoms occur. However, measurement of organ weights and histological
examination showed that surviving TNF/LT-/- mice had a similar degree of
organ damage as the surviving TNF/LT+/+ mice and were therefore not
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Figure 3. Relative lung (A), liver (B) and spleen (C) weights of surviving TNF/LT-/- (n=10),
TNF/LT+/+ (n=5) and control mice ( n=3). Data are presented as mean and SD. Relative
organ weight was calculated as: wet organ weight/body weight at day 22. Differences
between TNF/LT-/- and TNF/LT+/+ mice were significant (by Mann-Whitney U test) for liver
(P=0.00) and spleen (P=0.03).
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Figure 4. Lung scores of surviving TNF/LT-/- (n=10) and TNF/LT+/+ (n=5) mice. Data are
presented as mean and SD. There was no significant difference between groups (Mann-
Whitney U test).
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Figure 5. Representative sections of lung (A, B), liver (C, D), and spleen tissue (E, F) from
TNF/LT-/- (A, C, E) and TNF/LT+/+ (B, D, E) mice. Animals were killed 22 days after
zymosan and tissue sections were stained with hematoxylin-eosin.
FE
BA
C D
73
protected completely against MODS. In other words, MODS can still develop in
the absolute absence of TNF-α and LT-α.
It is generally accepted that TNF plays a critical role in systemic inflammation.
The current observation that TNF/LT-/- mice had better survival and clinical
condition than TNF/LT+/+ mice in the ZIGI model support the importance of
TNF in the development of MODS. Jansen et al. 18 could show two peaks of
TNF-α immunoreactivity in the serum of mice after zymosan injection. The first
peak occurs in the first phase while the second peak is detectable in the third
phase, when MODS-like symptoms occur in the mice. Shayevitz et al. 23 also
observed elevated plasma TNF-α levels in the first phase of the model, but they
give no data for the third phase. Jansen et al. 18 also found that the LPS-
stimulated TNF-α production by peritoneal macrophages was strongly elevated
in the second and third phase of the model. Recently published data by Burdon
et al. 14 also suggest a major role for TNF in the ZIGI model. They observed an
increased level of TNF-α mRNA in the livers and lungs of mice that were in the
third phase. Similar results were found in our lab, although our data suggest that
TNF-α mRNA in the lungs was already elevated in the second –recovery- phase
of the model (unpublished results). In an experiment with TNF p55 receptor
knockout mice Burdon et al. found no mortality or weight loss of these mice in
the third -MODS-like- phase at all. Moreover, they found similar
histopathological changes as described above in the lungs and liver of TNF-Rc-
p55+/+ mice at day 14, but no changes could be observed in the lungs of the
TNF-Rc-p55-/- mice, and changes in the liver could only be observed in 50% of
the TNF-Rc-p55-/- mice. So, although the findings of Burdon et al. are to a large
extent similar to ours, there are some differences. These differences might be
due to the fact that they used a different type of knockout mice than we did
(TNF-Rc-p55-/- versus TNF/LT-/-). While TNF-Rc-p55-/- possess TNF p75
receptors, Burdon at al. could not detect any TNF-α mRNA in the lungs and
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livers of TNF-Rc-p55-/- mice at any time point: thus it is unlikely that the TNF
p75 receptor plays a role in the development of organ damage.
Several experiments have been conducted with substances that might counteract
the effects of TNF in the ZIGI model. Administration of IL-10 improved both
mortality and morbidity and also reduced organ damage 13,19. Although IL-10 is
not a specific TNF inhibitor, it downregulates its production 24. Treatment of the
mice with chlorpromazine, a phenothiazine known to inhibit TNF-α production
in endotoxic shock models 25, resulted in reduced organ damage, although it did
not affect survival 21. Treatment of the mice with V1q, an antibody against TNF-
α resulted in a higher survival rate 20. Thus, all these anti-TNF treatments were
beneficial to some extent.  However, none of the treatments could completely
prevent MODS in mice.
The improvement in morbidity and mortality in TNF/LT-/- mice raises questions
about the mechanisms that are responsible for the organ damage in the ZIGI
model. A possible explanation for the reduced morbidity and mortality in the
TNF/LT-/- mice is the observed absence of neutrophil infiltration in the lungs
and livers of these mice. Impaired recruitment of neutrophils in TNF/LT-/- mice
was observed earlier by Netea et al. 26 in animals that were infected with
Candida Albicans. TNF is an important stimulus of the expression of adhesion
molecules such as E-selectin and ICAM-1 27 and a reduced expression of
adhesion molecules in TNF/LT-/- mice may impair neutrophil recruitment.
Apart from stimulating neutrophil recruitment, TNF is also able to strongly
potentiate the function of neutrophils, resulting in superoxide production 28.
Since superoxide production may cause tissue damage 29, a reduced capacity of
neutrophils from TNF/LT-/- mice to produce superoxide may be beneficial in
the ZIGI model.
Since TNF/LT-/- mice still develop organ damage, it appears that, although TNF
plays an important role in the pathogenesis, it can not be the only mediator
responsible for MODS in mice. In the last couple of years, several mediators
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have been proposed which could be important in this respect. An experiment in
our laboratory with IL-1ß-/- mice showed that survival and clinical condition of
these mice were not different from IL-1ß+/+ mice in the ZIGI model
(unpublished observations), indicating that it is unlikely that IL-1ß plays a
crucial role in the pathophysiology. Another mediator that may be important is
nitric oxide (NO). Cuzzocrea et al. suggest an important role of NO in zymosan
induced MODS in rats 30, but experiments in our laboratory with a selective
iNOS inhibitor and with iNOS-/- mice did not confirm this (manuscript in
preparation). Complement factors have also been suggested to mediate MODS
in mice. Nieuwenhuijzen et al. 31, Mahesh et al. 32 and Miller et al. 33 all
observed a reduced mortality in C5 deficient mice after zymosan administration,
but organ damage was not prevented in these mice.  IL-6 might also play a role
in the development of zymosan-induced organ damage 18,34, but a recent
experiment in our lab with IL-6-/- mice did not show a lower mortality of these
mice (unpublished observations).
The ZIGI model is widely used to investigate the pathophysiology of MODS 12-
14,23. As opposed to animal models that are used to study sepsis, the ZIGI model
is of long duration. This provides the opportunity to study the process of chronic
inflammation that leads to MODS development. Because the early mortality in
the ZIGI model suddenly increased dramatically in our experiments, most likely
as the result of changing conditions within our central animal facility, we
introduced a small modification to the ZIGI model. This modification consists of
an aseptic intraperitoneal injection of 40 µg LPS six days before the
intraperitoneal injection of zymosan. This way, the immune system of the
animals is triggered before they receive zymosan, which prevents an excessive
mortality rate in the first days after zymosan; the subsequent course of the model
remains essentially unchanged. The effect of this LPS dose is limited and
transient and does, in itself, not lead to any organ damage.
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In conclusion, TNF-deficient mice exhibit significantly improved survival
during zymosan-induced MODS. Also, the clinical condition appears to be
better than in the wildtypes. Still, surviving animals from both groups eventually
display a similar degree of organ damage. Thus, in this murine model, the
absence of TNF does not completely protect against MODS. This implies that
interventions directed only at TNF will not be sufficient in the prevention of
MODS. Thus, as Arthur Baue pointed out 35, it is an illusion that we will be able
to prevent MODS by a single “magic bullet”. Instead, multiple agents may be
necessary to modulate rather than block an excessive or continuing
inflammatory response.
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Pentoxifylline does not improve outcome
in a murine model for the multiple organ
dysfunction syndrome.
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ABSTRACT
Objective: To investigate the effects of pentoxifylline (PTX) administration in a
murine model for the multiple organ dysfunction syndrome (MODS).
Design: Prospective double-blind randomized animal study
Setting: University research laboratory
Interventions and measurements: Sixty C57BL/6 mice were given an aseptic
intraperitoneal injection of LPS, followed after six days by zymosan (day 0) in a
dose of either 0.9 or 1.0 mg/g body weight. Starting at day 0, mice were
administered PTX in a dose of 80 mg/kg body weight or saline per os every 8 h.
At day 17, surviving animals were killed and their liver, lungs, spleen and
kidneys were collected.
Results: Mortality, course of body temperature, body weight and macroscopic
lung damage were similar between zymosan-treated groups. Administration of
PTX did not result in a significantly improved survival, body temperature, body
weight or macroscopic lung damage. In addition, there were no significant
differences in organ weights between mice that received PTX and mice that
received PBS. Although PTX inhibited the LPS-induced increase in TNF-α and
IL-6 expression (but not the IL-1β expression) at both mRNA and protein level
in a murine macrophage cell line, TNF-α mRNA expression in the livers of
PTX-treated mice was not significantly inhibited.
Conclusions: The results reported here do not support the hypothesis that PTX
improves outcome in zymosan-induced multiple organ dysfunction in mice.
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INTRODUCTION
Over the past decades, advances in the support of vital organ functions have
transformed acute life-threatening illness from a rapidly lethal event to a chronic
state that is potentially survivable. Unfortunately, the development of intensive
care medicine has created a phenomenon called the multiple organ dysfunction
syndrome (MODS). MODS is a cumulative sequence of progressive
deterioration of organ systems. It usually starts with respiratory trouble, leading
to the acute respiratory distress syndrome (ARDS) and is followed by
dysfunction of the liver, gut and kidneys. Remarkably, these organs are not
necessarily involved in the primary disease 1,2. MODS may evolve after a variety
of insults like, for instance, major trauma or severe bacterial infection. It is
generally believed to be the result of an overwhelming host response resulting in
systemic inflammation 1,3,4. Once MODS develops, morbidity and mortality
rates are high. MODS is the leading cause of death for patients admitted to an
ICU. Elucidation of the mechanisms and mediators involved is necessary to
develop adequate treatment protocols. This type of research requires invasive
procedures and collection of tissue samples which are virtually impossible to
perform on patients. Therefore, we have developed an animal model for MODS
3,5,6, which is used widely to study systemic inflammation in relation to organ
failure 7-9. After a single insult in the form of an intraperitoneal challenge with
zymosan rodents suffer an acute, peritonitis-like phase that is followed by an
apparent recovery. Thereafter, a gradual deterioration occurs, characterized by
increasing organ damage and dysfunction 5. Recently, a minor modification has
been introduced: 'priming' of the mice with a small amount of LPS, which in
itself does not cause any organ damage at all, 6 days prior to zymosan improves
the reproducibility of the model, especially with respect to the mortality in the
acute phase, while subsequent development of MODS remains unaltered 6.
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Previous measurements, in the circulation, on isolated peritoneal cells 10, and at
organ level 11 have suggested an important role in this process for several pro-
inflammatory cytokines, especially tumor necrosis factor-α (TNF-α). However,
since strategies directed at counteracting TNF-α have only been partially
successful 12-14, targeting multiple cytokines at the same time appears to be
necessary.
Pentoxifylline (PTX) is a methylxanthine derivative that has been used for
treatment of chronic occlusive arterial disease because of its rheological actions
15. PTX acts primarily by increasing red blood cell deformability, by reducing
blood viscosity and by decreasing the potential for platelet aggregation and
thrombus formation 16. In addition, PTX has effects on the inflammatory
response.
It has been shown to improve survival in sepsis models by decreasing TNF-α,
interleukin-1β (IL-1β) and interleukin-6 (IL-6) levels 17,18 and to inhibit the
lipopolysaccharide(LPS)-stimulated production of multiple cytokines in alveolar
macrophages 19. PTX is known to inhibit phosphodiesterase, thereby increasing
cytoplasmic cyclic adenosine monophosphate levels and resulting in serious
inhibition of TNF-α gene transcription 20. Next to inhibiting cytokines, PTX is
also known to reduce the TNF-α-induced upregulation of E-selectin in
endothelial cells 21, which inhibits the adhesion of neutrophils. It also inhibits
adhesiveness, degranulation and superoxide production of activated neutrophils
22,23 and the production of nitric oxide by macrophages 24.
Because of its ability to counteract multiple pro-inflammatory mediators
simultaneously, PTX would seem a potentially useful agent to attenuate the
generalized inflammatory response leading to the organ failure observed in
MODS. In the present study we investigated the effects of PTX administration
in the murine model for MODS.
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MATERIAL AND METHODS
In vitro experiments
Murine macrophage-like cells from the J774.A1 cell line were grown to
confluence in Dubecco’s Modified Eagle’s Medium and pre-incubated in sixfold
with pentoxifylline (0.1 mg/ml and 1 mg/ml) 1 h prior to the addition of LPS (1
µg/ml). In experiment 1, cells were harvested for RNA extraction and
quantification (see below) 6 h after the addition of LPS. In experiment 2, the
culture supernatants were collected 24 h after stimulation with LPS. TNF-α
concentrations in the supernatants were measured with specific radio immuno
assay (RIA) as described previously 10. IL-6 concentrations in the supernatants
were measured with Enzyme Linked Immuno Sorbent Assay (ELISA) according
to the manufacturer’s instructions (Biosource, Etten-Leur, the Netherlands).
Animals
The experiment was performed with 63 C57BL/6 mice, 7 to 9 weeks old and
weighing 20-25 g. The animals were fed standard chow (Hope Farms RMB-H,
Woerden, The Netherlands) and acidified water ad libitum. The day/night cycle
was 12/12. Before use, the animals were allowed to acclimatize for 5 days. The
principles of laboratory animal care (NIH publication No. 86-23, revised 1985)
were followed, and the experiment was approved by the Animal Ethics Review
Committee of the Radboud University Nijmegen.
Zymosan-induced generalized inflammation
The zymosan-induced generalized inflammation model for MODS has been
described extensively previously 3,5,6,10,25. Briefly, mice were given an aseptic
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intraperitoneal injection of 40 µg LPS (Escherichia coli, Sigma Chemical, St
Louis, MO) dissolved in 200 µl of phosphate buffered saline (PBS), followed
after six days by zymosan (day 0). Zymosan A (Sigma Chemical) was sterilized
by gamma radiation (5 kGray) and homogeneously suspended in sterile paraffin
oil (25 mg/ml) by high frequency vibration during 1 h. After sonification, the
suspension was sterilized again at 100°C for 80 min. All suspensions were
freshly made before use. Zymosan was given intraperitoneally in a dose of either
0.9 or 1.0 mg/g body weight.
Experimental design
Animals were randomly assigned to 5 groups. Group 1 and 2 (15 mice each)
received zymosan in a dose of 0.9 mg/g body weight, groups 3 and 4 (15 mice
each) received zymosan in a dose of 1.0 mg/g body weight. Group 5 (6 mice)
functioned as untreated control group. Survival, body temperature and body
weight were monitored daily. Starting at day 0, mice were administered PTX in
a dose of 80 mg/kg body weight (groups 1 and 3) or PBS (groups 2 and 4) every
8 h. PTX powder (Sigma Chemical, St. Louis, MO) was dissolved in PBS and
made freshly every day. Both PTX and PBS were administered per os in a
volume of 200 µl. At day 17, surviving animals were killed and their liver,
lungs, spleen and kidneys were collected and weighed. Lung damage was
assessed macroscopically, using an arbitrary lung score: 0: no hemorrhages 1:
hemorrhagic spots covering approximately 1-25% of the lung surface; 2:
confluent hemorrhagic spots covering approximately 25-50% of the lung
surface; 3: great areas of hemorrhaging covering 50-75% of the lung surface; 4:
completely hemorrhagic lungs (75-100% of the surface covered with
hemorrhages). The livers and lungs were snap-frozen in liquid nitrogen and
stored at  –80°C for subsequent mRNA extraction.
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Quantitative Reverse Transciptase Polymerase Chain Reaction
Frozen livers and lungs were homogenized. Total RNA from cultured murine
macrophages, livers and lungs was extracted with the guanidinium thiocyanate-
phenol-chloroform method according to Chomczynski and Sacci 26. RNA
concentration was determined by spectrophotometric measurements with a
GeneQuant II RNA/DNA calculator (Amersham Pharmacia Biotech, Uppsala,
Sweden). The purity of precipitated total RNA was ascertained by 1% agarose
gel electrophoresis. Isolated RNA was used as a template for the production of
first strand cDNA using random hexamers. Relative quantification of TNF-α,
IL-1β and IL-6 mRNA was performed with a TaqMan real-time RT-polymerase
chain reaction (PCR) assay on a ABI PRISM 7700 Sequence Detector (Applied
Biosystems, Foster City, CA). Quantification of the amount of TNF-α, IL-1β
and IL-6 in unknown samples was accomplished using a standard curve to
determine the starting concentration of target. The standard curves were
generated using RNA from a mouse macrophage cell line (J774.A1) that was
stimulated with LPS (1 µg/ml) for 6 h (TNF-α and IL-1β) or 4 h (IL-6). In order
to correct for variations in cDNA concentrations between samples, cytokine
gene expression was normalized by dividing the starting concentration of target
by the starting concentration of constitutively expressed 18S ribosomal RNA
(endogenous control). Oligonucleotide primers and TaqMan probe were
designed with use of the Primer Express 1.0 software (Applied Biosystems). The
sequence (5’-3’) of forward primer, reverse primer, and probe were
CCCAGACCCTCACACTCAGATC, CCTCCACTTGGTTTGCT and
CGAGTGACAAGCCTGTAGCCCACGT respectively, for TNF-α,
GGACAGAATATCAACCAACAAGTGAT,
ATTACACAGGACAGGTATAGATTCTTTCCT and
AACGACAAAATACCTGTGGCCTTGGGC, respectively, for IL-1β and
TGTATGAACAACGATGATGCACTT,
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GGTACTCCAGAAGACCAGAGGAAAT and
AACGACAAAATACCTGTGGCCTTGGGC respectively, for IL-6. The probe
for IL-6 was a Taqman Minor Groove Binder (MGB) probe. The PCR
conditions were as follows: for amplification of the cytokine product, 25 ng of
cDNA was added to the PCR mixture consisting of 25 µl TaqMan Mastermix
(Applied Biosystems), 12.5 pmol fluorescent probe (Applied Biosystems) and
15 pmol of each primer in a final volume of 50 µl.  For amplification of the 18S
rRNA product, the PCR mixture consisted of 25 µl TaqMan Mastermix and 2.5
µl of pre-developed TaqMan 18S rRNA control kit (Applied Biosystems).
Again, the final volume was 50 µl. Thermal cycling conditions were 2 min at
50°C and 10 min of initial denaturation at 95°C to activate Taq Gold
polymerase, followed by 40 cycles of 2-step PCR consisting of 15 s at 95°C and
1 min at 60°C.
Statistics
Kruskal-Wallis tests were used to test whether variation among experimental
groups was greater than expected by chance. When significant, Dunn’s multiple
comparisons tests were performed to assess statistical significance between
individual groups.
RESULTS
In vitro experiments
PTX inhibited the LPS-induced TNF-α and IL-6 production in murine
macrophage-like cells in a dose-dependent manner, both at mRNA and protein
level. In contrast, this was not the case for IL-1β mRNA, which expression
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seemed to be increased rather than decreased by PTX (Figure 1). For instance, at
the highest dose used, PTX suppressed TNF-α mRNA and protein levels by 95
and 77 %, respectively and increased IL-1β mRNA levels by 29 %.
In vivo experiments
The in vivo effect of PTX was examined in two separate groups of animals,
receiving zymosan in doses of 0.9 and 1.0 mg/g body weight, respectively. In
previous, unpublished, experiments in our laboratory the higher dose led to a
slightly more pronounced degree of illness. However, in the current experiment
the clinical parameters were not significantly different between groups receiving
0.9 or 1.0 mg/g zymosan. Therefore, the data from both groups were combined
to make up figures 2 and 3, which represent the primary outcome parameters.
After the injection of LPS on day –6, all animals became ill for one day,
indicated by a transient loss in body weight. By the time they received zymosan
(day 0), the animals had recovered completely. The injection of zymosan
induced an acute peritonitis rendering all animals very ill during the first two
days, as reflected by a ruffled fur, diarrhea, lethargic behavior and a decrease in
body weight and temperature. During the second phase of the illness (day 3 to 5)
the condition of the surviving animals appeared to return to normal, reflected by
the display of natural curiosity, grooming, a smooth fur, and disappearance of
diarrhea. Body temperature was restored and animals gained weight again. From
approximately day 6 onwards, animals entered the third - MODS-like - phase,
indicated by lethargic behavior, breathing difficulties, weight loss and a decrease
in body temperature.
Administration of PTX did not result in significantly improved survival, body
temperature, body weight or lung score (Figure 2). Organ weight was
significantly higher in lung and spleen of zymosan-treated animals than in
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Figure 1. Effect of PTX on LPS-induced cytokine production in J774.A1 cells. Average
values (+SD) for mRNA (black bars) and protein (white bars) concentration of TNF-α
(A), IL-6 (B) and IL-1β (C). Samples were measured in sixfold. LPS concentration was
1 µg/ml. Asterisks denote significant differences from cells stimulated with LPS alone
(Kruskal-Wallis test, if significant followed by Dunn’s multiple comparison test,
P<0.05).
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Figure 2. Effect of PTX administration on survival, clinical symptoms and lung scores.
A: Survival of mice that received PTX (▲, n=30) in a dose of 80 mg/kg or PBS (○,
n=30) every 8 h. B: Average body temperature and average body weight (C) of
untreated control mice (x, n=6) and surviving zymosan-treated mice that were treated
with PTX (▲, n=18) or PBS (○, n=20). D: Average (+ SD) lung scores of surviving
mice that were treated with PTX (n=18) or PBS (n=20).
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untreated controls (Figure 3). However, this parameter of organ damage was
unchanged between mice that received PTX and mice that received PBS. Also,
TNF-α and IL-1β mRNA expression in the liver, which was strongly and
significantly increased after zymosan administration, was not significantly
inhibited in PTX-treated mice (Figure 4).
DISCUSSION
Administration of PTX did not have beneficial effects on clinical condition and
mortality in zymosan-induced inflammation. Upregulation of TNF-α and IL-1β
mRNA in the liver was not prevented by PTX. Damage of the liver, spleen and
kidneys has only been assessed indirectly by measuring organ weight since it
has been demonstrated previously to correlates well with the development of
histopathological damage 27. We did investigate the course of disease after
administration of both 0.9 and 1.0 mg zymosan/g body weight since, depending
on the batch of zymosan, the clinical course and mortality may change rather
strongly with dose (unpublished observations). However, this was not the case
in the present experiment and in both series, essentially representing separate
and independent experiments, PTX administration remained uneffective.
A previous study in our laboratory revealed that during zymosan-induced
MODS, the mRNA expression of multiple cytokines is strongly increased 11.
The in vitro experiments in the current study show that PTX inhibited the LPS-
induced TNF-α mRNA expression and protein production by macrophage-like
cells, as was described previously in primary macrophages 19,28. The IL-6
production was also inhibited by PTX, but this was not the case for the IL-1β
mRNA expression. Earlier studies on the effects of PTX on the LPS-induced IL-
1β and IL-6 production by primary macrophages have yielded conflicting results
19,28-31. Possibly, these differences might be caused by variations in underlying
disease in the species from which the macrophages were harvested.
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Figure 3. Effect of PTX administration on organ weight. Average values (+SD) for
liver (A), lungs (B), spleen (C) and kidneys (D) in surviving zymosan-treated mice
that received PTX (n=18), PBS (n=20) and in untreated control mice (n=6).
Asterisks denote significant differences with respect to untreated controls
(Kruskal-Wallis test, if significant followed by Dunn’s multiple comparison test,
P<0.05).
92
Figure 4. TNF-α and IL-1β mRNA expression in liver tissue. Average
values (+SD) for surviving mice treated with zymosan in a dose of 0.9
mg/g body weight (black bars, n=11 and 10, respectively) and for
untreated control mice (white bar, n=6). Mice in the experimental groups
were treated with either PTX or PBS. Asterisks denote significant
differences with respect to untreated controls (Kruskal-Wallis test, if
significant followed by Dunn’s multiple comparison test, P<0.05).
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In the present study, no effect of PTX on TNF-α and IL-1β mRNA expression in
the liver was seen in vivo and this is probably the main reason why no beneficial
effects of PTX on morbidity and mortality were observed either. It cannot be
ruled out that in other tissues than the liver mRNA levels of these cytokines
were reduced, but since earlier experiments in our laboratory showed that TNF-
α and IL-1β mRNA levels are most strongly upregulated in the liver during the
MODS-like phase of the animal model 11, a potential reduction in mRNA levels
is most likely to be detected in the liver.
A potential problem using PTX is its short half-life. Pharmacokinetic studies
have shown that intraperitoneally administered PTX has a half-life in the
circulation of only 4 to 7 minutes in healthy mice 32,33. PTX is rapidly hydrolized
to 1-(5-hydroxyhexyl)-3-7-dimethylxanthine, which is suggested to exhibit
effects similar to those observed for PTX 34. However, this metabolite is also
eliminated rapidly 32 33. To reduce stress for the animals and to achieve a more
gradual uptake of PTX in the circulation and in the tissues, PTX was
administered orally every 8 h (instead of intraperitoneally) in the present study.
PTX is extensively and rapidly absorbed from the gastrointestinal tract, both in
animals and in humans 16.
The results from the present study are in contrast with previous in vivo studies in
which PTX was administered repeatedly. Kremsner et al. 35 found that daily
intraperitoneal injections of 1 mg PTX abolished serum TNF bioactivity in
Plasmodium berghei-infected mice, thereby preventing signs of cerebral
malaria. Edwards et al.36 administered IL-2, which is an antineoplastic agent, to
mice with pulmonary metastases and found that intraperitoneal injections of
PTX in a dose of 50 mg/kg every 12 h suppressed the rise in serum TNF levels
that normally follows IL-2 administration. This way, IL-2 toxicity was limited
without affecting antitumor efficacy. Louie et al. 37 reported that intraperitoneal
injections of PTX in a dose of 20 mg/kg every 8 h shortened mean survival in
mice with systemic Candida albicans infection, due to an increased organ fungal
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burden. However, serum TNF-α and IL-6 levels were not decreased by PTX. In
a murine colitis model 38, intraperitoneal injections of PTX (5mg/kg) twice daily
significantly reduced the severity of colonic histopathology and
myeloperoxidase levels. However, TNF-α could not be detected in serum of any
treatment group. Koo et al. 18 administered PTX intraveneously in a dose of 50
mg/kg during a 90 minute infusion period to rats that were subjected to
polymicrobial sepsis and found that this treatment attenuated the rise in plasma
TNF-α, IL-1β, and IL-6 levels.
Taken together, these studies emphasize the potential beneficial effects of PTX
on clinical parameters in various pathologies. In some cases, reduced circulating
levels of TNF-α, IL-1β and IL-6 were reported. However, circulating cytokine
levels might not reflect their activity at organ level. In the current study, we
measured cytokine mRNA in liver tissue, which might be expected to correlate
better with actual cytokine activity at organ level. The PTX doses used in the
studies mentioned above varied between 10 and 200 mg/kg/day and were
therefore lower than that employed in the current study (240 mg/kg/day). In
these studies, however, PTX was administered intraperitoneally or intravenously
instead of per os. In previous studies in our laboratory (unpublished data), PTX
was also administered intraperitoneally every 8 h in a dose of 80 mg/kg. Here,
no beneficial effect of PTX on mortality, morbidity or cytokine levels was found
either. Since intraperitoneal injections every 8 h for an extended time period is
rather burdensome for the animals and oral PTX is effective in patients with
vascular diseases 39, we opted for oral administration in the current experiment.
Because we did not find any beneficial effects of intraperitoneally administered
PTX either, it seems unlikely that the absence of effects of PTX in the current
study can be explained by this difference in experimental design.
PTX has also been used in clinical trials. Hoffman et al. 40 observed a shorter
duration of required ventilator support, a shorter intensive care unit stay and a
lower incidence of renal failure in patients at risk for developing MODS if they
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were treated with intravenous PTX. Staubach et al. 41 found that continuous
intravenous infusion of PTX resulted in an improved cardiopulmonary
dysfunction in septic patients. However, serum TNF-α and IL-6 bioactivity were
not different between the study groups, so the beneficial effects of PTX in this
study could be the result of its rheological instead of its anti-inflammatory
effects.
The results reported here do not support the hypothesis that PTX has beneficial
effects on outcome in zymosan-induced murine MODS. One should be always
be careful to extrapolate the results of animal studies to human pathology.
However, the data at least constitute a warning regarding the potential (lack of)
effictiveness of PTX in human patients at risk for MODS. Other agents that
target multiple inflammatory mediators might yield better chances to provide
treatment options and remain a topic of future investigation.
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organ dysfunction syndrome in mice is not
mediated by inducible nitric oxide
synthase.
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ABSTRACT
OBJECTIVE: To examine the role of inducible nitric oxide synthase (iNOS) in
the development of the multiple organ dysfunction syndrome (MODS) in a
murine model by using either a selective iNOS inhibitor or iNOS knockout
mice.
DESIGN: Prospective randomized laboratory study.
SETTING: Central animal laboratory and experimental laboratory.
SUBJECTS: A total of 50 inbred C57BL/6 mice, 39 iNOS knockout (-/-) mice
and 30 wildtype (+/+) mice, 7 to 9 weeks old, weighing 20-25 g.
INTERVENTIONS:  Mice received an aseptic intraperitoneal injection of 40 µg
lipopolysaccharide (LPS) followed by zymosan at a dose of 1 mg/g body weight
6 days later (day 0). In experiment I, C57BL/6 mice additionally received
intraperitoneal injections with 5 mg aminoguanidine or saline every 12h, from 4
days after the injection of zymosan onward. In experiment II, both iNOS-/- mice
and corresponding wildtype (iNOS+/+) mice were treated with LPS and
zymosan.
MEASUREMENTS AND MAIN RESULTS:
In all animals the injection of zymosan induced an acute peritonitis, followed by
an apparent recovery. From approximately day 6 onwards, animals entered the
third - MODS-like - phase, indicated by weight loss, a decrease in body
temperature and significant mortality.
Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and
immunochemistry revealed a strongly increased expression of iNOS mRNA and
iNOS protein in livers of mice in the last phase. However, neither the in vivo
administration of aminoguanidine to C57BL/6 mice, nor the complete absence
of iNOS enzyme (iNOS-/- mice) had a beneficial effect on survival rate, body
temperature, or body weight. In addition, relative lung-, liver- and spleen
weights and lung scores were not different between experimental groups.
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CONCLUSIONS: The current results strongly argue against an essential and
causative role of iNOS in the development of organ damage in our murine
model of MODS.
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INTRODUCTION
The development of the multiple organ dysfunction syndrome (MODS) by
patients suffering from multiple trauma, shock, pancreatitis, or peritonitis is a
major problem in the intensive care unit. MODS is a syndrome characterized by
the progressive deterioration of the function of various organs, starting mostly
with the adult respiratory distress syndrome (ARDS), followed by dysfunction
c.q. failure of the liver, gut, kidneys, and the circulation. Once MODS develops,
the morbidity and mortality remain high. Support of normal organ function is
currently the best way to prevent MODS 1-3.
It is now generally accepted that MODS results from an uncontrolled, systemic
inflammatory response rather than infection per se 4-9. The development of
adequate treatment protocols depends on further elucidation of the mechanisms
and mediators involved. This type of research requires invasive procedures that
cannot be easily performed on humans. Therefore we have developed an animal
model for MODS 10,11, which has been adopted by several laboratories,
sometimes in modified versions 12-14. In this model, intraperitoneal
administration of zymosan in a paraffin oil suspension leads to a three-phasic
illness, consisting of an episode of acute illness, followed by a period of
apparent recovery and, finally, the development of MODS-like symptoms.
Nitric oxide (NO) is a reactive and readily diffusible gas produced from L-
arginine by one of three nitric oxide synthase (NOS) enzymes, namely, neuronal
NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS).  eNOS is
normally present in vascular endothelium, nNOS is found in neurones of the
brain and in the enteric nervous system. The inducible isoform of the enzyme,
iNOS, is found in endothelium, epithelium, and inflammatory cells. iNOS is
induced by cytokines and lipopolysaccharide (LPS), and produces large
quantities of NO for extended periods of time. In the early 1990s the paradigm
was put forward that the constitutively expressed eNOS and nNOS are critical to
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normal physiology, whereas induction of iNOS causes tissue injury 15,16.
Although NO per se may not be detrimental, it can, at least in vitro, react with
superoxide to produce peroxynitrite, which has been shown to induce direct
cellular injury 16-18.
During inflammation and shock, proinflammatory cytokines and bacterial wall
components may induce iNOS. It has been proposed that in these conditions the
NO produced may damage tissue, which ultimately leads to organ failure 19-21.
Furthermore, iNOS-derived NO (or peroxynitrite) may also contribute to tissue
damage indirectly by inducing proinflammatory mediators 18.
Since the development of MODS is thought to be driven by an uncontrolled
inflammatory reaction, upregulation of iNOS may be expected. Indeed, in
previous experiments with zymosan-induced MODS in mice we found that the
capacity of peritoneal macrophages to produce NO is strongly increased 22. This
raises the question if iNOS is essential in the pathophysiology of MODS.
Therefore, we examined the course of MODS – in our murine model - both in
the presence of an iNOS inhibitor and in the complete absence of iNOS, by
using iNOS knockout mice.
MATERIAL AND METHODS
Animals
Experiments were performed by using 50 inbred C57BL/6 mice (Charles River,
WIGA, Germany), 39 iNOS knockout (-/-) mice and 30 wildtype (+/+) mice, 7
to 9 weeks old, weighing 20-25 g.  INOS-/- mice were generated as described
previously 23. iNOS-/- and iNOS+/+ mice were intercross progeny
(C57Bl/6x129Sv). Colonies were maintained at the Central Animal Laboratory
(Nijmegen, Netherlands). All mice were housed under specific pathogen-free
conditions during breeding and experiments.  Animals were housed in filter-top
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cages and fed a standard chow and acidified water at libitum. iNOS-/- deficiency
of mice was routinely controlled during breeding by RT-PCR using primers
bridging the neo cassette replacement of the first 4 exons of the iNOS gene:
upstream 5’-CCC TAA GAG TCA CCA AAA TGG-3’, downstream 5’-CTA
CAG TTC CGA GCG TCA AA-3’. The animals were fed standard chow (Hope
Farms RBM-H, Woerden, the Netherlands) and acidified water ad libitum. The
day/night cycle was 12/12. Before use, the animals were allowed to acclimatize
for 5 days. The experiments were approved by the Animal Ethics Review
Committee of the Faculty of Medicine, University of Nijmegen.
Zymosan-induced generalized inflammation
The animal model for MODS has been characterized previously 11. Briefly, mice
received an aseptic intraperitoneal injection of 40 µg lipopolysaccharide (LPS)
(E.coli, Sigma, St Louis) dissolved in 200 µl PBS, six days prior to zymosan
administration. Zymosan A (Sigma, St. Louis, MO) was sterilized by gamma
radiation (5 kGray) and  homogenously suspended in sterile paraffin oil (25
mg/ml) by high frequency vibration during 1 h. After sonification, the
suspension was sterilized again in a waterbath at 100°C for 80 min. All
suspensions were freshly made before use. Zymosan was given in a dose of 1
mg/g body weight.
Experimental design of in vivo studies
In experiment I, 37 C57BL/6 mice were used: 17 mice received intraperitoneal
injections of  5 mg aminoguanidine in 100 µl 0.9% NaCl every 12 h, starting 4
days after the injection of zymosan, while another 17 mice received 100 µl of
0.9% NaCl only. Three mice did not receive zymosan or any other treatment and
functioned as untreated controls.  Survival, body weight and body temperature
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were monitored. At day 14, surviving mice were killed by cervical dislocation
and the lungs, liver, and spleen were collected and weighed. Lung damage was
assessed macroscopically, using an arbitrary lung score: 0: no hemorrhages 1:
hemorrhagic spots covering approximately 1-25% of the lung surface; 2:
confluent hemorrhagic spots covering approximately 25-50% of the lung
surface; 3: great areas of hemorrhaging visible covering 50-75% of the lung
surface; 4: completely hemorrhagic lungs (75-100% of the surface covered with
hemorrhages).
In experiment II, 24 iNOS-/- mice and 25 corresponding wildtype (iNOS+/+)
mice were used. 3 iNOS-/- mice and 6 iNOS+/+ functioned as untreated
controls. Survival, body weight and body temperature were monitored. At day
16, surviving mice were killed by cervical dislocation and the lungs, liver, and
spleen were collected and weighed. Lung damage was assessed
macroscopically.
In additional experiments with C57BL/6 mice, animals were killed at day 12 and
lungs, liver, spleen and kidneys were collected. INOS gene expression was
measured by quantitative Reverse Transcriptase Polymerase Chain Reaction
(RT-PCR) and iNOS protein in liver tissue was detected by
immunohistochemistry.
Immunohistochemistry
Tissues were fixed for 4 h in phosphate buffered 3.8% formaldehyde and 4 µm
sections were prepared from paraffin-embedded tissues. After deparaffinization,
nonspecific adsorption was minimized by incubating the sections in 10% normal
goat serum in phosphate-buffered saline for 15 min. The sections were then
incubated with 1:50 dilution of primary rabbit anti-murine iNOS antibody (sc-
650, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or with phosphate-
buffered saline (control sections) for 1 h at room temperature. Specific labeling
106
was detected with a biotin-conjugated goat anti-rabbit immunoglobulin G
(BA1000, Vector Laboratories, Burlingame, CA, USA) and an avidin-biotin
alkaline phosphatase complex. Tissues were counterstained with methyl green
(Sigma, St. Louis, MO, USA).
Quantitative Reverse Transcriptase Polymerase Chain Reaction
After collection, organs were snap-frozen in liquid nitrogen and stored at –80°C.
Frozen organs were homogenized and total RNA was extracted with the
guanidinium thiocyanate-phenol-chloroform method according to Chomczynski
and Sacci 24. RNA concentration was determined by spectrophotometric
measurements with a GeneQuant II RNA/DNA calculator (Amersham
Pharmacia Biotech Ltd). The purity of precipitated total RNA was ascertained
by 1% agarose gel electrophoresis.
Isolated RNA was used as a template for the production of first strand cDNA
using random hexamers. Relative quantification of iNOS mRNA was performed
with a TaqMan real-time RT-polymerase chain reaction (PCR) assay on a ABI
PRISM 7700 Sequence Detector (Perkin-Elmer Applied Biosystems Inc.). The
standard curve was generated using RNA from a mouse macrophage cell line
(J774-A1) that was stimulated with LPS (4 µg/ml) and human IFN-γ (0.85
µg/ml) for 8 h. iNOS gene expression was evaluated with the constitutively
expressed 18S ribosomal RNA as endogenous control. Oligonucleotide primers
and TaqMan probe were designed with use of the Primer Express 1.0 software
(Perkin-Elmer Applied Biosystems Inc).
The PCR conditions were as follows: for amplification of the iNOS product, 25
ng of cDNA was added to the PCR mixture consisting of 25 µl TaqMan
Mastermix (Perkin Elmer Corporation, Foster City, CA, USA), 12.5 pmol
fluorescent probe and 15 pmol of each primer in a final volume of 50 µl.  For
amplification of the 18S rRNA product, the PCR mixture consisted of 25 µl
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TaqMan Mastermix and 2.5 µl of pre-developed TaqMan 18S rRNA control kit
(Perkin-Elmer). Again, the final volume was 50 µl. Thermal cycling conditions
were 2 min at 50°C and 10 min of initial denaturation at 95°C to activate Taq
Gold polymerase, followed by 40 cycles of 2-step PCR consisting of 15 s at
95°C and 1 min at 60°C. Samples and standards were measured in duplicate.
Macrophage nitrite production
The effects of aminoguanidine on LPS-induced nitrite production were
examined both in a mouse macrophage cell line and in isolated mouse peritoneal
macrophages.
Cells from the cell line J774.A1 were resuspended in Dubecco’s Modified Eagle
Medium (Nutrient mixture F-12, Life Technologies, Paisley, UK) supplemented
with 10% fetal calf serum, L-glutamine (0.29 mg/ml), penicillin (100 U /ml) and
streptomycin (100 µg/ml) to a concentration of 1*106 cells/ml. The cell
suspension was transferred to a 96 wells plate (250 µl/well).
Peritoneal macrophages were collected as follows: after cervical dislocation, 4
ml of ice-cold sterile phosphate buffered saline (PBS) containing 0.38% citrate
was injected into the peritoneum of C57BL/6 mice. The PBS was withdrawn
under aseptic conditions, cells were washed twice in cold PBS, and resuspended
in RPMI1640 medium (Life Technologies, Paisley, UK) supplemented with Na-
pyruvate (0.11 mg/ml), Gentamycinsulphate (0.05 mg/ml) and L-glutamine
(0.29 mg/ml) to a final concentration of 1*106 cells/ml.
After allowing the cells to attach for 24 h, the supernatants were removed and
the cells were incubated for 24 h at 37°C (5% CO2) with medium containing 10
µg LPS/ml with or without aminoguanidine (in a final concentration of 0.1 or
1.0 mM). Then 30 µl aliquots from these cultures were incubated for 20 minutes
at room temperature with 0.005 U nitrate reductase and 7.5 µg NADPH in a
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total volume of 50 µl. Subsequently these aliquots were incubated for 10 min at
room temperature with 50 µl of Griess reagent. The absorbancy at 540 nm was
determined in a microtiter plate reader. Nitrite was quantified using NaNO2 as a
standard. Standards were measured in triplicate, samples in quadruplicate.
Statistical analysis
Statistical significance of differences in mortality between experimental groups
was analyzed using Fisher’s exact test. Statistical significances of differences in
body temperature and –weight and of differences in lung score were analyzed
using the Mann-Whitney U test. One-way ANOVA was used to test whether
variation among relative organ weights of experimental groups was greater than
expected by chance. (According to the Kolmogorov-Smirnov-method, data were
sampled from populations that follow Gaussian distributions.) When significant,
Tukey-Kramer post-tests were performed to assess statistical significance
between individual groups. P-values smaller than 0.05 were considered
significant.
RESULTS
Zymosan-induced generalized inflammation
After the injection of LPS on day –6, all animals became ill for one day,
indicated by a transient loss in body weight. By the time they received zymosan
(day 0), the animals had recovered completely.  The injection of zymosan
induced an acute peritonitis rendering all animals very ill during the first two
days, as reflected by a ruffled fur, diarrhea, lethargic behavior and a decrease in
body weight and temperature. During the second phase of the illness (day 3 to 5)
the condition of the surviving animals appeared to return to normal, reflected by
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the display of natural curiosity, grooming, a smooth fur, and disappearance of
diarrhea. Body temperature was restored and animals gained weight again. From
approximately day 6 onwards, animals entered the third - MODS-like - phase,
indicated by lethargic behavior, breathing difficulties, weight loss and a decrease
in body temperature.
iNOS expression in liver tissue
Quantitative RT-PCR revealed a strongly increased expression of iNOS mRNA
in livers of C57BL/6 mice in phase 3. Average normalized iNOS expression in
livers of untreated control mice was 0.03±0.01, while in livers of mice that were
in phase 3 this was 75.27±19.42 (Table 1). Also, in 2 out of 4 livers of mice that
were killed in phase 3, expression of iNOS protein could be detected by
immunohistochemistry, whereas this was not the case in livers of untreated
controls or in livers of iNOS-/- mice that were killed in phase 3 (Figure 1). The
strong upregulation of the iNOS gene in phase 3 seemed to be limited to liver
tissue.  In lungs, spleen, and kidneys, iNOS mRNA expression was somewhat
upregulated in phase 3, but this upregulation was below the threshold of
accurate quantification (data not shown).
Effect of aminoguanidine on zymosan-induced MODS
In both J774-A1 cells and isolated mouse peritoneal macrophages, the in vitro
administration of aminoguanidine inhibited the LPS-induced nitrite production
in a dose-dependent fashion. In both cell types, the highest dose of
aminoguanidine effectively abolished the LPS-induced nitrite production since
the resulting concentrations were similar to those produced in the absence of
LPS (Figure 2).
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Table 1. Expression of iNOS mRNA in liver from untreated
C57BL/6 control mice and zymosan-treated C57BL/6 mice that
were in the (MODS-like) phase 3 of the model.
Sample Cycle
threshold
value
Normalized
iNOS expressiona
Control mouse 1
Control mouse 2
Control mouse 3
Phase 3 mouse 1
Phase 3 mouse 2
Phase 3 mouse 3
39.25
39.57
39.53
27.58
28.56
28.83
  0.04
  0.02
  0.02
80.07
76.03
69.71
a Cycle threshold (Ct) values for both iNOS and 18S rRNA expression were transformed to ng
of cDNA by use of calibration curves for iNOS and 18S rRNA expression in the J774.A1 cell
line.  Subsequently, normalized iNOS expression was calculated as 100x(iNOS/18S rRNA).
Samples and standards were measured in duplicate.
The in vivo administration of aminoguanidine in C57BL/6 mice, starting 4 days
after the injection of zymosan, did not result in an improved survival rate as
compared to animals that were injected with saline only (Figure 3A), survival
rates being 59% and 53%, respectively. Also, there was no difference in average
body temperature (33.4±2.9°C vs 33.7±2.5°C) and average relative body weight
(83.4±12.3% vs 85.9±15.9%) between the aminoguanidine- and saline treated
groups at day 14 (Figure 3B and 3C). Relative lung, liver and spleen weights
were elevated in both groups compared to organs of untreated control animals,
indicating organ damage. However, there were no significant differences in
either organ weights or macroscopic lung score (Figure 4) between the
aminoguanidine- and saline treated groups.
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Figure 1. Immunohistochemical staining of iNOS protein in liver tissue.
A: untreated C57BL/6 control mice; B: zymosan-treated C57BL/6 mice;
C: zymosan-treated iNOS -/- mice. Livers of zymosan-treated mice were
harvested in the third - MODS-like - phase of the model.
B
C
A
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Figure 2. Nitrite production by J774.A1 cells (A) and isolated peritoneal macrophages (B).
Cells were incubated for 24 h with LPS (10 µg/ml) and variable concentrations of
aminoguanidine. Dotted lines represent basal nitrite concentration (produced in the absence
of LPS). Values represent average + SD (n=4).
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Figure 3. Effect of aminoguanidine administration on survival and clinical symptoms.
Survival (A) of zymosan-treated C57BL/6 mice that received an ip injection of 5 mg
aminoguanidine (▲, n=17) or saline (■, n=17) every 12 h, starting 4 days after the injection
of zymosan. Average body temperature (B) and average relative body weight (C) of untreated
control mice (●, n=3) and surviving zymosan-treated C57BL/6 mice that were treated with
aminoguanidine (▲, n=10) or saline (■, n=9). Relative body weight was calculated as (body
weight / body weight at day 0)x100%. Data represent average values + SD.
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Figure 4. Effect of aminoguanidine administration on organ weight and lung score. Average
values (+SD) for relative lung (A), liver (B) and spleen (C) weight and lung score (D) in
surviving C57BL/6 mice treated with aminoguanidine (n=10) or saline (n=9) and in
untreated control mice (n=3). Relative organ weight was calculated as (organ weight / body
weight)x100%. Lung scores in control mice were 0.  * p<0.05 versus controls.
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Development of MODS in iNOS-/- mice
INOS knockout (-/-) mice and their corresponding wildtypes (+/+) also exhibited
a similar course of illness. Survival rates of iNOS-/- and iNOS+/+ mice at day
16 were equal at 29% ( Figure 5A). Also, the course of body temperature and
body weight was similar in both groups. Although surviving iNOS-/- mice
displayed a lower average body temperature (28.1±4.3°C vs 31.6±2.3°C, figure
5B) and a lower average relative body weight (73.9±6.2% vs 82.0±6.8%, figure
5C) at day 16 than the iNOS+/+ mice, these differences remained non-
significant. Relative organ weights were elevated in both groups, as compared to
organs of untreated control animals, although the difference in relative liver
weight between iNOS-/- and untreated control mice did not reach statistical
significance. There were, however, no significant differences in organ weights
and macroscopic lung scores between iNOS-/- and iNOS+/+ mice (Figure 6).
DISCUSSION
The current results strongly argue against an essential and causative role of
iNOS in the development of organ damage in our murine model of MODS.
Neither treatment in vivo with an inhibitor of iNOS activity nor the complete
absence of iNOS in the knockout mice leads to improved survival, abation of
clinical signs for illness or attenuation of organ damage.
In our model, intraperitoneal administration of zymosan to rodents leads to an
immediate shock-like state, followed by a short period of apparent recovery.
Thereafter, the clinical condition of the animals deterioriates again with time,
concomitant to a gradual development of organ dysfunction. Organ damage is
characterized by histopathological changes and abnormal values of serum
markers 11. In addition, there are signs of generalized inflammation 22,25. As
such, the animals display a number of characteristics commonly observed during
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Figure 5. Survival and clinical symptoms in iNOS knockout and wildtype mice. Survival (A) in
zymosan-treated iNOS-/- (▲, n=24) and iNOS +/+ (■, n=25) mice. Average body
temperature (B) and average relative body weight (C) of surviving zymosan-treated iNOS-/-
(▲, n=7), iNOS+/+ (■, n=7) and untreated control mice (●, n=10). Relative body weight
was calculated as (body weight / body weight at day 0)x100%. Data represent average values
+ SD.
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Figure 6. Organ weight and lung score in iNOS knockout and wildtype mice. Average values
(+SD) for relative lung (A), liver (B) and spleen (C) weight and lung score (D) in surviving
iNOS-/- (n=7), iNOS+/+ (n=7), and untreated control mice (n=10) mice. Relative organ
weight was calculated as (organ weight / body weight)x100%. Lung scores in control mice
were 0. * p<0.05 versus controls.
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MODS. Because the early mortality in the ZIGI model recently increased
dramatically in our experiments, most likely as the result of changing conditions
within our central animal facility, we introduced a small modification to the
ZIGI model. This modification consists of an aseptic intraperitoneal injection of
40 µg LPS six days before the intraperitoneal injection of zymosan. This way,
the immune system of the animals is triggered before they receive zymosan,
which prevents an excessive mortality rate in the first days after zymosan; the
subsequent course of the model remains essentially unchanged. The effect of
this LPS dose is limited and transient and does, in itself, not lead to any organ
damage.
 There exists ample evidence that iNOS plays an important role in the
pathophysiology of several inflammatory disease states, such as chronic
inflammatory bowel disorders 26, arthritis 27, and glomerulonephritis 28. In our
animal model, MODS is caused by zymosan-induced generalized inflammation.
The present immunohistochemisty and quantitative RT-PCR data clearly
indicate that in the third, MODS-like phase, both iNOS protein and mRNA are
strongly upregulated in liver tissue. In addition, earlier experiments in our
laboratory have shown that both unstimulated and LPS-stimulated NO
production by peritoneal cells is elevated during this period 22. These findings
can be taken to suggest that NO produced by iNOS may play a role in the onset
and propagation of MODS.
Aminoguanidine is a selective inhibitor of iNOS 29,30, although its affinity is not
very high 31. Results from our in vitro experiments show that aminoguanidine
suppresses, dose-dependently, NO production in both a mouse macrophage cell
line (as was reported previously 29) and in isolated peritoneal macrophages. In
the in vivo experiment, aminoguanidine has been given twice daily from day 4
after zymosan administration onwards when the first, shock-like phase, is over.
The experiment was designed this way since intraperitoneal injections every 12
h with either aminoguanidine or saline starting immediately after the zymosan
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dose cause a high mortality in the first days (data not shown). Apparently,
during this phase the animals are too weak to cope with the stress resulting from
the necessary manipulation twice every 24 h. Since MODS-like symptoms do
not occur until day 6 or later, it seems unlikely that iNOS inhibition before day 4
will be of any influence on the clinical symptoms in the third phase. In the
present study, 5 mg of aminoguanidine has been administered in vivo every 12h
to C57BL/6 mice. This dose is comparable to doses used in earlier studies in
other rodent models where iNOS inhibition led to an effective reduction of
disease. For instance, Cross et al. 32 found significantly less pathology in mice
treated with aminoguanidine in a model for multiple sclerosis, while Connor et
al. 31 found that aminoguanidine is able to suppress joint inflammation
associated with adjuvant-induced arthritis in rats in a dose-dependant manner.
Altogether, the fact that aminoguanidine does not improve the course of MODS
in our model constitutes the first argument against an essential role for iNOS in
the development of this syndrome.
The second argument stems from the outcome of the experiment with iNOS-/-
mice. These animals have been used before in a number of studies with models
for diseases, where iNOS is involved in the pathology, and have often exhibited
a reduced morbidity and mortality if compared to the wildtype iNOS+/+ mice.
For instance, Ling et al. 33 found that kidneys of iNOS-/- mice were protected
against acute ischemic renal failure, while Hollenberg et al. 34 observed a lower
mortality in iNOS-/- mice than in iNOS+/+ mice in a septic shock model.
Although there are also reports that iNOS-/- mice may display a higher morbidy
and/or mortality in sepsis 35, the fact that there are differences in clinical
parameters between iNOS-/- and iNOS+/+ mice indicates that iNOS-/- mice can
be a useful tool for studying disease processes. However, in our model of
zymosan-induced generalized inflammation, iNOS-/- mice do not show either
improved survival or clinical condition, or a lesser degree of organ damage. This
is in agreement with the results of Van de Loo et al. 36, who did not find a lesser
120
degree of zymosan-induced joint inflammation in iNOS-/- mice. In itself, this
result does not unequivocally prove that the iNOS enzyme is not important in
our model. It is possible that iNOS-/- mice develop mechanisms to compensate
for their inability to produce iNOS. However, if taken together with the result
from the aminoguanidine experiment, the current results make a strong
argument against an essential role for iNOS in zymosan-induced MODS.
In seeming contrast to the present data, Cuzzocrea et al. 21,37 have reported
experiments which suggest that NO is indeed involved in zymosan-induced
organ damage. Administration of L-NAME, a nonselective NOS inhibitor, led to
a reduced zymosan-induced organ injury and mortality in rats. This apparent
discrepancy might be explained by the fact that their experiments were of much
shorter duration than ours (48 h versus 12-17 days). Therefore, the model they
used must be considered as a model for nonseptic shock rather than for MODS
occurring as the result of a chronic systemic inflammatory response. In addition,
since L-NAME is a nonselective inhibitor of NOS it cannot be ruled out that the
beneficial effects of L-NAME administration are somehow related to the
inhibition of eNOS/nNOS instead of iNOS.
Generally speaking, the paradigm that NO produced by iNOS causes tissue
injury and therefore specific inhibition of this enzyme in inflammation is
beneficial, may be too simplistic. In fact, NO can function as an antioxidant
during the inflammatory response. Infiltrating neutrophils are an important
source of oxidants. Under pathological conditions, the synthesis of reactive
oxidant species by neutrophils is enhanced, resulting in lipid peroxidation and
subsequent tissue damage, thus possibly contributing to the development of
MODS. NO is also known to be an antiadhesive molecule, and by inhibiting the
recruitment of neutrophils it might reduce oxidative stress. Furthermore, it reacts
with superoxide to inactivate its biologic activity, and NO donors have been
shown to reduce H2O2-induced injury and inflammation 15,16. Still, in our model
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the putative suppression of NO production by either iNOS inhibition or iNOS
absence, does not lead to deterioration of the disease parameters either.
In previous experiments we have found that during the development of MODS
the ability of peritoneal macrophages to produce both superoxide anion (O2-) and
NO is elevated 22. Apart from being an oxidant species itself, O2- can induce the
formation of the hydroxyl radical (.OH). Like peroxynitrite, hydroxyl radical is a
key trigger of DNA single strand breakage, with the subsequent activation of
poly(ADP-ribose) synthetase (PARS) resulting in cell damage 38. Thus, the
formation of O2- might be considered as a contributing factor in the development
of MODS. However, administration of superoxide dismutase and catalase in the
acute phase after zymosan administration did not improve subsequent organ
damage observed in rats  39.
In conclusion, the results reported here do not support an important and
causative role for iNOS in zymosan-induced organ damage in mice. Elucidation
of the mechanisms directly responsible for the observed organ damage remains a
topic for future investigation.
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ABSTRACT
Matrix metalloproteinases (MMPs) have been implicated as mediators of tissue
damage in several inflammatory diseases. Since the Multiple organ dysfunction
syndrome (MODS) is thought to result from systemic inflammation,
overactivation of MMPs could contribute to the organ damage observed. The
expression and activity of several MMPs were studied in a murine model for
MODS. 60 mice were given an aseptic intraperitoneal injection of
lipopolysaccharide, followed after six days by zymosan. At days 2, 5, 8, 12 and
16 after the injection of zymosan, groups of mice were killed and the liver,
lungs, spleen and kidneys were collected for either RNA extraction, gelatinase
zymography and collagenase (MMP-1 and –13) assays (6 mice per time point)
or immunohistochemistry (3 mice per time point). A group of 9 mice did not
receive zymosan and acted as control group. The expression of MMP-2 mRNA
in zymosan-treated mice was strongly upregulated in liver tissue only. For
MMP-9, this was the case in all organs examined. Quantitative gelatin
zymography demonstrated the near complete absence of any gelatinase activity
in tissues from control mice. However, in the liver, lungs and especially the
spleen of zymosan-treated animals, a significantly increased activity of proform
and active MMP-2 and –9 was observed with time. Overall, MMP-1 and –13
activities were very low in all samples from liver and lung. In the spleen,
however, high levels of MMP-1 and –13 were observed in zymosan-treated
animals. Immunohistochemical staining for MMP-2 was detected in the liver
and the spleen but not in lung and kidney tissue of zymosan-treated animals.
Staining for MMP-9 could be detected in liver, lung and spleen tissues of
zymosan-treated mice. For both MMPs, staining appeared to be limited to
phagocytes. In conclusion, the data suggests a role for MMPs, especially MMP-
9, in the pathogenesis of MODS.
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INTRODUCTION
A major cause of death in the surgical intensive care unit is the multiple organ
dysfunction syndrome (MODS). The cumulative sequence of progressive
deterioration of organ systems starts mostly in the lungs and is followed by
dysfunction of the liver, gut and kidneys, which organs are not necessarily
involved in the primary disease 1,2. This destructive pathway may be
encountered after a variety of serious insults like major trauma or severe
bacterial infection. Most likely, it is the result of an overwhelming host response
resulting in systemic inflammation 1,3,4. Once MODS develops, morbidity and
mortality rates are high. Treatment for patients with MODS is still largely
supportive. Further development of treatment and prevention modalities requires
elucidation of the mechanisms and mediators involved. Such research requires
invasive procedures and collection of tissue samples which are virtually
impossible to perform on patients. Therefore, we have developed an animal
model for MODS 3,5,6, which is used widely to study systemic inflammation in
relation to organ failure 7-9. Mice that receive intraperitoneal zymosan display a
gradual development of MODS-like symptoms.
Disruption of tissue architecture will result in organ dysfunction. The
extracellular matrix is central to tissue architecture and homeostasis.
Remodelling of the extracellular matrix is largely mediated by enzymes from the
matrix metalloproteinase (MMP) family, which consists of a growing number of
secreted and membrane-bound metalloendopeptidases. During inflammation,
they play an important role in the control of cellular interactions with their
environment 10. MMPs have been implicated as mediators of tissue damage in
several inflammatory diseases, such as rheumatoid arthritis 11, osteoarthritis 12
and atherosclerosis 13. MMPs have also been related to systemic inflammation.
Several studies have suggested an important role for MMPs in the development
of the adult respiratory distress syndrome (ARDS) 14,15 and it has been shown
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recently that circulating MMP-9 concentrations are elevated in critically ill
patients 16.
It seems entirely possible that overactivation of MMPs could contribute to the
organ damage observed in MODS. Gene expression of MMPs is regulated by
several factors, among them cytokines. Previous research in our laboratory has
demonstrated that the development of MODS in mice is, at least in part, the
result of overexpression of TNF-α 17,18 and other cytokines (Volman et al.,
unpublished data). Since proinflammatory cytokines are known to induce MMP
production and secretion 19,20, MMP activity may be upregulated in the various
tissues affected. If so, specific inhibition of these enzymes may be a new target
for preventing organ dysfunction. The present study presents the first data on the
expression and activity of several gelatinases and collagenases in the murine
model for MODS.
METHODS
Zymosan-induced generalized inflammation
The zymosan-induced generalized inflammation model for MODS has been
described extensively 3,5,6,17,18. Zymosan was given intraperitoneally at a dose of
0.8 mg/g body weight.
The current experiment was performed using 69 C57BL/6 mice, 7 to 9 weeks
old and weighing 20-25 g. The experiment was approved by the Animal Ethics
Review Committee of Nijmegen University.
Experimental design
Mice were divided into three groups. Group 1 consisted of 50 animals: at days 2,
5, 8, 12 and 16 after the injection of zymosan, 6 mice were taken randomly,
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killed by cervical dislocation and the liver, lungs, spleen and kidneys were
collected for RNA extraction, gelatinase zymography and collagenase assays.
Organs were snap-frozen in liquid nitrogen and stored at –80°C.  At days 2, 5, 8,
and 16 after zymosan, another 3 mice were killed and their organs were
collected for immunohistochemistry. Group 2 consisted of 9 mice that did not
receive zymosan and acted as controls. The organs of 6 control mice were
collected for biochemistry, while those of the other 3 were used for
immunohistochemistry. In all mice, the lung damage was assessed
macroscopically, using an arbitrary lung score (see legend to Figure 2). To
monitor the clinical course and mortality due to zymosan treatment, a group of
10 additional mice (group 3) was treated with LPS and zymosan and their body
temperature, body weight and survival were monitored until day 16, when
surviving animals were killed.
Quantitative Reverse Transcriptase Polymerase Chain Reaction
RNA extraction and cDNA synthesis were described previously 6. Relative
quantification of MMP-2 and MMP-9 mRNA was performed with a TaqMan
real-time RT-polymerase chain reaction (PCR) assay on an ABI PRISM 7700
Sequence Detector (Applied Biosystems, Foster City, CA). Quantification of the
amount of target in unknown samples was accomplished using a standard curve
to determine the starting concentration of target. The standard curve for MMP-2
was generated using RNA from a mouse fibroblast cell line (NIH-3T3) after
stimulation with human interleukin-1β (100 ng/ml) for 24 h. The standard curve
for MMP-9 was generated using RNA from a mouse macrophage cell line
(J774.A1) treated with LPS (1 ng/ml) for 12h. In order to correct for variations
in cDNA concentrations between samples, MMP-2 and -9 gene expression was
normalized by dividing the starting concentration of target by the starting
concentration of constitutively expressed 18S ribosomal RNA (endogenous
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control). The PCR conditions for target and 18S rRNA products were as
described previously 6. Since we were primarily interested in temporal changes
in gene expression, results are expressed in a relative way. Upregulation of gene
expression at any time point was calculated as the median of normalized gene
expressions divided by the median of normalized gene expression in untreated
control mice.
Oligonucleotide primers and TaqMan probe were designed with use of the
Primer Express 1.0 software (Applied Biosystems). The sequence (5’-3’) of
forward primer, reverse primer, and probe were
CTGGAATGCCATCCCTGATAA, CAAACTTCACGCTCTTGAGACTTT
and TGAAGAAGTAGCTATGACCACCGCCCTG, respectively, for MMP-2.
The respective sequences for MMP-9 were AAGGGGCGTGTCTGGAGATT,
GGTACTGGAAGATGTCGTGTGAGT, and
CCCAGAGCGTCATTCGCGTGGATA.
Zymography
Frozen organs were pulverized, extracted and dialysed as described previously
21. Gelatin zymography was performed to quantify the presence of both activated
and latent forms of the gelatinases MMP-2 (gelatinase A) and MMP-9
(gelatinase B) in the tissue extracts, as described previously 21.
Collagenase assays
A selection of tissue extracts (liver, lungs, and spleen extracts of control mice
and mice killed at days 8 and 12 after zymosan, n=5 per group) were analysed
for the collagenases MMP-1 and MMP-13. MMP activity was measured using
quenched fluorogenic peptide substrates that were synthesized according to the
method described by Drijfhout et al. 22. Fluorescein was coupled to the peptides
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via the cystein’s thiol function using iodacetamide-fluorescein. All MMP assays
were performed in Tris buffer (50 mM Tris, 5 mM CaCl2, 150 mM NaCl, 1 µM
ZnCl2, 0.01% Brij-35, 0.02% NaN3; pH 7.5) in the presence of EDTA-free
general proteinase inhibitor cocktail Complete (Roche, Mannheim, Germany) to
prevent conversion of the fluorogenic substrates by proteinases other than
MMPs. Further improvement of the assay specificity for MMPs was achieved by
determining the difference in substrate conversion in the presence or absence of
the synthetic MMP inhibitor BB94. MMP-1 activity was determined 23 with the
selective fluorogenic substrate TNO113-F (5 µM). MMP-13 activity was
determined 24 using the selective fluorogenic substrate TNO013-F (5 µM). The
rate of substrate conversion (RFU /s; relative fluorescence units per second) at
30°C (λex 485 nm, λem 530 nm; Cytofluor4000; PerSeptive Biosystems) was
normalized to the amount of protein present in the tissue extract and expressed
as RFU/s per mg protein.
Immunohistochemistry
Tissues were fixed in phosphate buffered 3.8% formaldehyde for 4 h at room
temperature. From paraffin-embedded tissues 4 µm sections were prepared.
After deparaffinization, endogenous peroxidase activity was blocked with 3%
H2O2 in phosphate-buffered saline. Nonspecific adsorption was minimized by
preincubating the sections in 20% normal horse serum in phosphate-buffered
saline for 10 min. The sections were then incubated overnight at 40C   with 1:200
dilution of primary goat anti-human MMP-2, 1:400 goat anti-mouse MMP-9
antibody (sc-6838 and sc-6841, Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) or phosphate-buffered saline (control sections). Labeling was detected
with a biotin-conjugated horse anti-goat immunoglobulin G serum (BA9500,
Vector Laboratories, Burlingame, CA, USA) and an avidin-biotin peroxidase
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complex. Tissues were counterstained with hematoxylin (Klinipath, Duiven, the
Netherlands). All sections for MMP-2 and MMP-9 were stained simultaneously.
RESULTS
Clinical course
The injection of zymosan induced an acute peritonitis rendering all animals very
ill during the first two days, as reflected by a ruffled fur, diarrhea, lethargic
behavior and a decrease in body weight and temperature (Figure 1). During the
second phase of the illness (day 3 to 5) the condition of the surviving animals
appeared to return to normal, reflected by the display of natural curiosity,
grooming, a smooth fur, and disappearance of diarrhea. Body temperature was
restored and animals gained weight again. From approximately day 6 onwards,
animals entered the third - MODS-like - phase, indicated by lethargic behavior,
breathing difficulties, weight loss and a decrease in body temperature. The
progression of lung damage, which is reflected by an increased lung score from
day 5 onwards, is illustrated in figure 2.
mRNA expression
In the liver, mRNA for both MMP-2 and -9 was strongly upregulated compared
to untreated control animals. This was especially the case in the third, MODS-
like, phase of the model, where the expression of both MMP-2 and -9 mRNA
was 15 times higher than in control animals (Figure 3A). Figure 3 gives, for
reasons of clarity, median values only. In order to demonstrate the degree of
variation observed between animals, the expression of MMP-2 and -9 mRNA in
the liver of all individual animals is illustrated in Figure 4. In the lungs there was
no upregulation of MMP-2 mRNA, but MMP-9 mRNA levels were 15 times
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Figure 1. Survival and clinical symptoms after zymosan administration. Panel A depicts
survival; Body temperature (B) and body weight (C) were measured daily and are depicted as
average + SD in a group which comprised 10 animals at the start of the experiment.
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Figure 2. Development of lung damage. Bars represent average values + SD. (n=9, except for
day 12 where n=6) for the macroscopic lung score; 0: no hemorrhages 1: hemorrhagic spots
covering approximately 1-25% of the lung surface; 2: confluent hemorrhagic spots covering
approximately 25-50% of the lung surface; 3: large areas of hemorrhage covering 50-75% of
the lung surface; 4: completely hemorrhagic lungs (75-100% of the surface covered with
hemorrhages).
higher than in controls at day 5 (Figure 3B). In the spleen and kidneys, the
mRNA expression of MMP-2 was upregulated only marginally while the
increase in MMP-9 mRNA was much more pronounced (Figure 3C and 3D).
Bioactivity
Quantitative gelatin zymography demonstrated the near complete absence of any
gelatinase activity in tissues from control mice. However, in the liver of
zymosan-treated animals, a significantly increased activity of proform (60 kDa)
and active (53 kDa) MMP-2 and of proform (100-108 kDa) and active (80-92
kDa) MMP-9 was observed with time. This was especially the case for
proMMP-9, which showed a strong and lasting elevation from day 5 onwards
(Figure 5A). The same was true for the lungs (Figure 5B). The highest
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gelatinase activity was observed in the spleen (Figure 5C). In contrast to the
other tissues, the spleen also exhibited very high levels of active MMP-9,
peaking around day 8.
In the kidneys, only low levels of gelatinase activity were observed at any time
point (data not shown).
Next to the specific bands of proform and active MMP-2 and -9, the zymograms
contained other gelatinase activities, especially at higher kDa values, which
represent dimeric forms or complexes between MMPs and inhibitors. All
activities were inhibited by EDTA (data not shown). For each sample, we have
also calculated the total gelatinase activity on each zymogram. Figure 6
illustrates that the total gelatinase activity was strongly increased during the
development of organ failure.
In addition to the gelatinase activities, we also measured collagenase bioactivity
in a selected number of samples. Overall, MMP-1 and –13 activities were very
low in all samples from liver and lung (Figures 7A and 7B, respectively). In the
liver, the MMP-13 activity at day 8 was significantly lower than in controls. In
the lungs, both MMP-1 and –13 activities were significantly lower in the
zymosan-treated mice than in the control animals. Much higher levels of MMP-
1 activity were found in the spleen from zymosan-treated mice (Figure 7C).
MMP-13 activities in were much lower, but still significantly higher than in the
untreated control animals.
Immunohistochemistry
Immunohistochemical staining for MMP-2 and MMP-9 could be observed in
organs of mice that had been killed at the various time points in the model.
However, because of the great variability in staining between animals and the
relative small number of animals per time point, it was not possible to quantify
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Figure 3. Upregulation of MMP-2 (●) and MMP-9 (∆) mRNA in liver (A), lung (B), spleen
(C) and kidney (D) tissues, quantitated by a real-time RT-PCR. The degree of upregulation
was calculated for each animal as the mRNA expression at any time point in relation to the
median mRNA expression in control mice. Data are represented as medians (n=6).
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Figure 4. mRNA expression of MMP-2 (●) and MMP-9 (ο) in liver tissue of individual mice,
quantitated by a real-time RT-PCR.
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Figure 5. Tissue MMP-2 and MMP-9 activities. The activity of proMMP-2 (hatched bars),
active MMP-2 (double-hatched bars), proMMP-9 (open bars) and active MMP-9 (closed
bars) in liver (A), lung (B) and spleen (C) extracts were quantitated by gelatin zymography.
Data represent specific activity in arbitrary units/mg protein (average + SD, n=6). Bars
marked with an asterisk are significantly different from control animals (P<0.05, Mann-
Whitney U test). Bars marked with a circle indicate that testing was not possible due to an SD
of zero in one or more groups.
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Figure 6. Total tissue gelatinase activity. Bars represent average (+ SD, n=6) total
gelatinolytic activity measured on zymograms from liver (closed bars), lung (hatched bars)
and spleen (open bars). Bars marked with an asterisk are significantly different from control
animals (P<0.05, Mann-Whitney U test).
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Figure 7. Tissue MMP-1 and MMP-13 activities. The activity of MMP-1 (open bars) and
MMP-13 (closed bars) in liver (A), lung (B) and spleen (C) extracts was quantitated by
fluorogenic assays. Data represent specific activity in arbitrary units/mg protein (average +
SD, n=5). Bars marked with an asterisk are significantly different from control animals
(P<0.05, Mann-Whitney U test).
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any changes in the expression of these MMPs over time during the course of the
experiment.
MMP-2 was detected in zymosan-treated animals at all time points, i.e. in the
granulomatous lesions of the liver and in the red pulp of the spleen but not in
lung and kidney tissue of zymosan-treated mice. In untreated animals all tissues
were negative. Staining appeared to be limited to phagocyting, macrophage-like
cells (Figure 8).
MMP-9 could be detected in liver, lung and spleen tissues of zymosan-treated
mice at all time points. In untreated control animals, organs were negative
except for the spleen. Here, a slight degree of staining for MMP-9 was observed
although the reaction in spleen tissues from zymosan-treated mice was much
stronger. As for MMP-2, staining for MMP-9 was limited to phagocytes (Figure
9).
DISCUSSION
The data demonstrate that there is an upregulation of gelatinase mRNA and an
increased MMP activity in multiple tissues during the development of MODS in
mice. Organ damage in this model is accompanied by gradual and progressive
changes in wet and dry organ weights that correlate with increasing pathology.
Histopathological changes include progressive development of massive
hemorrhagic spots in the lungs and granuloma-like structures of mononuclear
cells in the liver. In the spleen, the distinct borders between red and white pulp
disappear and there are megakaryocytes and lymphocytes present in the red pulp
5.
In general, MMPs are not produced constitutively. Their expression is regulated
in a cell-specific manner by inflammatory mediators such as growth factors and
proinflammatory cytokines 25. Of the MMPs examined in the current study, the
expression of MMP-9 was increased most strongly. MMP-9 attacks basement
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Figure 8. Immunohistochemical staining for MMP-2. Staining was observed in phagocytes in
liver (A) and spleen (C; arrows) of zymosan-treated mice, but absent in liver (B) and spleen
tissues (D) of untreated control mice.
membrane collagen, elastin, and fibronectin, and also efficiently degrades
denatured collagens or gelatins of all types 19. It is secreted as a  zymogen and
processed to an active form via a conformational change at the catalytic site,
followed by autocatalysis 26. PMNs and endothelial cells contain a stock of
preformed MMP-9 in secretory vesicles 20,27, which enables them to release
MMP-9 very rapidly following specific stimuli. Although proMMP-9 can be
secreted by many cell types involved in the inflammatory response, the
immunohistochemical data indicate that in the present model MMP-9 is
produced by phagocytic cells, probably macrophages.
MMP-9 has been shown to cleave inactive TNF-α, such that active TNF-α is
released 28. In addition, MMP-9 gene expression by macrophages and PMNs and
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Figure 9. Immunohistochemical staining for MMP-9. Staining was observed in phagocytes in
liver (A) and spleen (C) tissues of zymosan-treated mice. Liver of untreated control mice (B)
was negative. Slightly stained cells were present in the red pulp of the spleen (D).
hence the release of proMMP-9 can be induced by TNF-α and IL-1β 19,20. Tissue
inhibitor of metalloproteinase-1 (TIMP-1) production by macrophages is not
affected by these cytokines 19, suggesting that an excess of MMP-9 molecules
due to a rise in TNF-α and IL-1β concentrations remains catalytically
competent.
It has been extensively reported that TNF-α levels are strongly elevated in
critically ill patients 16. Also, previous studies in our laboratory have shown that
in the third - MODS-like - phase of the murine model mRNA levels for TNF-α
and IL-1β are elevated in several organs, as are circulating TNF-α levels. It is
conceivable that elevated levels of TNF-α and/or IL-1β are responsible for the
increased activity of MMP-9 observed.
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We also observed an increased expression and activity of MMP-2 in the course
of the model, but this increase is weaker than for MMP-9 and remains limited to
spleen and liver tissue. Although MMP-2 has a substrate specificity which is
similar to MMP-9, its expression is regulated differently 27. ProMMP-2 is
constitutively expressed by many cell types 29, but its expression is also induced
by specific stimuli 30. Unlike MMP-9, MMP-2 is not induced by TNF-α and IL-
1β. Next to its gelatinase activity, MMP-2 cleaves proMMP-9, yielding active
MMP-9 30.
Basement membrane is the part of the extracellular matrix that is associated with
the vascular endothelium. It is also associated with hepatocytes and bile duct
epithelium in the liver, the alveolar epithelium in the lungs and epithelial cells
and glomeruli in the kidneys. An increased activity of MMP-2 and –9 might
threaten the integrity of basement membranes and may thereby lead to capillary
leakage, increased influx of inflammatory cells in tissues and organ damage.
The activity of the collagenases MMP-1 and MMP-13 is also increased in spleen
tissue at days 8 and 12 after zymosan. Since phagocytosis of zymosan results in
the production of MMP-1 by macrophages 31, it is possible that macrophages are
responsible for the increased production of MMP-1. Apart from its collagenase
activity, MMP-1 activates proMMP-2 and -9 30, thereby possibly contributing to
increased gelatinase activity. The activities of MMP-1 and –13 in liver and lung
tissues in zymosan-treated animals are significantly lower than in control
animals in most cases, but since MMP-1 and –13 activities in these organs are
very low to start with, this difference is probably not of any clinical relevance.
The results from PCR and zymography show that gelatinase mRNA expression
and activity in the lungs and spleen peak at days 5 to 8, whereas in the liver peak
expression and activity are reached later, at days 12 to 16. This is in agreement
with the occurrence of organ damage during the development of MODS in mice,
because in earlier studies we have observed that lung damage precedes liver
damage 5.
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MMPs have been studied in relation to generalized inflammation in mice before.
Pagenstecher et al. 32 have reported an increased expression of MMP genes
during LPS-induced endotoxemia in mice, suggesting that MMPs may
contribute to the development of organ damage in endotoxemia.
The results from the present study imply that administration of MMP inhibitors
might be beneficial in this MODS model. MMP inhibitors have been studied in
other models of critical illness. Carney et al. 33 have found that pretreatment of
pigs with COL-3, a combined MMP and elastase inhibitor, results in lower
levels of MMP-2 and –9 in bronchoalveolar lavage fluid and a lesser degree of
organ injury in an ARDS model. Another MMP inhibitor, GM-6001, has been
shown to improve survival in an endotoxic shock model in mice, probably by
inhibiting TNF-α processing and release 34.
In conclusion, our study suggests a role for MMPs, especially MMP-9, in the
pathogenesis of MODS. Intervention studies with MMP inhibitors could provide
additional evidence for this hypothesis. If intervention studies with animals
show promising results, MMP inhibitors might eventually provide a clinical
treatment option for patients who are at risk for MODS.
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SUMMARY
Unfortunately, our increased ability to keep critically ill patients alive has
yielded a new phenomenon: the multiple organ dysfunction syndrome (MODS).
MODS is defined as the presence of altered organ function in a severely ill
patient so that homeostasis cannot be maintained without intervention.
Regardless of the cause, MODS typically consists of the sequential dysfunction
of several organ systems, beginning with the lungs and followed by hepatic,
intestinal, renal, and eventually cardial dysfunction, although the exact order
may vary because of preexisting disease or the nature of the precipitating insult.
MODS usually occurs after various physiologic insults, which may include
pancreatitis, trauma, burns, shock, severe infection, aspiration, multiple blood
transfusions, and pulmonary contusions. There are two clinical observations that
strongly indicate that MODS is a systemic process. First, the organs where
damage occurs are not necessarily directly injured or involved in the primary
disease process. Second, there is usually a lag phase of days to weeks between
the primary insult and the development of remote organ dysfunction. These
observations suggest that endogenous circulating factors are involved in the
pathophysiology of MODS. Studies in critically ill patients show that increased
circulating levels of pro-inflammatory cytokines are associated with organ
dysfunction and an increased risk of death. It is now generally believed that
MODS is the result of a generalized inflammatory response (chapter 1).
The examination of the mechanisms behind MODS requires invasive procedures
that cannot be performed on humans. Therefore, animal studies and in vitro
studies are needed to elucidate the pathophysiological pathways that lead to
MODS. In our laboratory, an animal model for MODS has been developed. It is
called the zymosan-induced generalized inflammation (ZIGI) model and has
been adopted by other research groups as well (chapter 2).
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Intraperitoneal injection of zymosan in C57BL/6 mice leads to a three-phasic
illness starting with a peritonitis-like reaction. This first phase lasts for 2 days
and renders the animals very ill, which is apparent from a transient decrease in
body temperature, loss of body weight, and a mortality of up to 20%. After 2
days the surviving mice appear to recover, indicated by a normalization of body
temperature and weight. After about 7 days, the third phase sets in. This phase is
characterized by MODS-like symptoms, i.e. cachexia, tachypnea and
hypothermia. In addition, progressive changes in the morphology of the lungs,
liver, spleen and kidneys occur, also reflected by an increase in organ weight.
Hemorrhagic spots are found in the lungs evolving into macroscopically visible
massive hemorrhages, a process that can be quantitated by using a lung score.
An additional 20-30% of the animals die in this phase before the experiment is
terminated after 12 to 22 days.
A lot of research has focussed on identifying the mediators involved in the
development of MODS. Circulating inflammatory mediators are relatively easy
to measure, but may be a poor reflection of processes at organ level, where the
damage occurs. To devise logical interventions, possibly directed at multiple
cytokines, it is necessary to collect data on their expression at tissue level during
the development of MODS. For this purpose, we have performed a
comprehensive study quantitating the course of TNF-α, IL-1β, IL-6, MIF, IL-
12, IFN-γ and IL-10 mRNA expression in lung, liver, spleen and kidney, tissues
that exhibit increasing histopathological changes in time (chapter 3). During the
peritonitis phase, upregulation of cytokine mRNA was limited. During the
period of apparent recovery, cytokine mRNA expression strongly increased,
mostly reaching its maximum at day 9 when deterioration of the clinical
condition had already set in. The upregulation of TNF-α mRNA was most
pronounced, especially in the lungs and liver. Thus, interventions should
preferentially be targeted against multiple cytokines and, at least in this model,
there may be a treatment window well after the initial challenge.
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Previous research in our laboratory has shown that plasma TNF-α levels are
increased during the first 24 h after injection of zymosan, followed by a
prominent peak from day 8 onwards. Moreover, subsequent experiments have
revealed that interventions directed at TNF-α may mitigate the symptoms of
zymosan-induced MODS, indicating that TNF-α plays a prominent role in the
pathophysiology. Additional evidence for this hypothesis is provided by
experiments using TNF knockout mice. The complete absence of TNF results in
a significantly lower mortality in the ZIGI model (chapter 4). In addition, TNF
knockout mice exhibit a higher average body temperature and average body
weight than wildtype mice at day 22. However, at this time point, surviving
animals from both groups show similar and significant microscopic damage in
lungs, liver and spleen and an elevated average organ weight. Thus, although
TNF-deficient mice exhibit significantly improved morbidity and mortality, the
absence of TNF does not completely protect against zymosan-induced MODS.
Since strategies directed at counteracting TNF-α alone have so far only been
partially successful in preventing MODS in the murine model, targeting multiple
cytokines at the same time appears likely to have more beneficial effects..
Pentoxifylline (PTX) is a methylxanthine derivative that has been used for
treatment of chronic occlusive arterial disease because of its rheological actions.
PTX has effects on the inflammatory response as well. It has been shown to
decrease TNF-α, IL-1β and IL-6 levels in sepsis models. PTX is known to
inhibit phosphodiesterase, thereby increasing cytoplasmic cyclic adenosine
monophosphate levels. This strongly inhibits TNF-α gene transcription. Because
of its ability to counteract multiple pro-inflammatory mediators simultaneously,
PTX is a potentially useful agent to attenuate the generalized inflammatory
response leading to the organ failure observed in MODS. We have performed an
intervention study to investigate the effects of PTX administration (chapter 5).
Ex vivo, PTX inhibits the LPS-induced TNF-α and IL-6 production (but not the
IL-1β production) in J774.A1 macrophages in a dose-dependent manner, both at
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mRNA and protein level. Administration of PTX to zymosan-treated C57BL/6
mice does not result in a significantly improved survival, body temperature,
body weight or lung score. Also, no significant differences in organ weights
have been found between mice that received PTX and mice that received PBS.
TNF-α and IL-6 mRNA expression in the liver is similar in both groups and this
is probably the main reason why no beneficial effects of PTX on morbidity and
mortality have been observed. Altogether, these results do not support the
hypothesis that PTX has beneficial effects in zymosan-induced organ damage in
mice.
During inflammation and shock, proinflammatory cytokines and bacterial wall
components may induce nitric oxide synthase (iNOS).  NO produced by iNOS
has been proposed to cause tissue damage, either directly or indirectly by the
formation of peroxynitrite. We have investigated the role of iNOS in the
development of murine MODS using either a selective iNOS inhibitor
(aminoguanidine) or iNOS knockout mice (chapter 6). Quantitative reverse
transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry
reveal a strongly increased expression of iNOS messenger RNA (mRNA) and
iNOS protein in the livers of C57BL/6 mice in the third – MODS-like - phase of
the model. However, neither the in vivo administration of aminoguanidine to
C57BL/6 mice nor the complete absence of iNOS enzyme (iNOS knockout
mice) have a beneficial effect on survival, body temperature or body weight. In
addition, lung, liver, and spleen weights and lung scores are similar in the
various experimental groups. These results strongly argue against an essential
and causative role of iNOS in the development of murine MODS.
The extracellular matrix is central to tissue architecture and homeostasis.
Disruption of tissue architecture will result in organ dysfunction. Remodelling
of the extracellular matrix, either as part of physiological homeostasis and
development or as part of a pathological process, is to a large part mediated by
enzymes from the matrix metalloproteinase (MMP) family, which consists of a
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growing number of secreted and membrane-bound metalloendopeptidases.
During inflammation, they play an important role in the control of cellular
interactions with their environment. MMPs have been implicated as mediators
of tissue damage in several inflammatory diseases. MMPs have also been related
to systemic inflammation. Several studies have suggested an important role for
MMPs in the development of the adult respiratory distress syndrome (ARDS)
and it has been shown recently that circulating MMP-9 concentrations are
elevated in critically ill patients. It seems entirely possible that an overactivation
of MMPs could contribute to the organ damage observed in MODS. Gene
expression of MMPs is regulated by several factors, among them cytokines. An
experiment has been conducted to provide data on the expression and activity of
several gelatinases and collagenases in lungs, liver, spleen and kidneys during
zymosan-induced MODS (chapter 7). The expression of MMP-2 mRNA in
zymosan-treated mice is strongly upregulated in liver tissue only. For MMP-9,
this is the case in all organs examined. In the liver, lungs and especially the
spleen of zymosan-treated animals, a significantly increased activity of proform
and active MMP-2 and –9 is observed with time. MMP-1 and –13 activities are
very low in all samples from liver and lung. In the spleen, however, high levels
of MMP-1 and –13 are observed in zymosan-treated animals.
Immunohistochemical staining for MMP-2 is detected in the liver and the spleen
but not in lung and kidney tissue of zymosan-treated animals. Specific staining
for MMP-9 is present in liver, lung and spleen tissue of zymosan-treated mice.
For both MMPs, staining appears to be limited to phagocytes. These results
suggest a role for MMPs, especially MMP-9, in the pathogenesis of MODS.
Intervention studies with MMP inhibitors could provide additional evidence for
this hypothesis.
Since MODS does not seem to be driven by a single mediator, interventions
directed at multiple mediators seem the most promising approach for the future.
A major problem will be finding or designing agents that can modulate multiple
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mediators in a specific way at a specific time point of illness. Previous studies
directed at multiple mediators have been performed using treatments that were
not specific while the mechanisms of actions were often not entirely clear,
making interpretations of the results difficult. Hopefully, specific interventions
such as inhibiting multiple proinflammatory cytokines simultaneously, without
intervening with other cellular processes, will become possible in the near
future. This will improve our understanding of the underlying pathophysiology
of MODS and will eventually provide better treatment options in patients at risk
for or with MODS.
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Onze toegenomen mogelijkheden om patiënten die zich in een kritieke toestand
bevinden in leven te houden heeft helaas een nieuw fenomeen opgeleverd: het
multi-orgaan disfunctie syndroom (MODS). MODS wordt gedefinieerd als een
zodanige verslechtering van orgaanfuncties in een ernstig zieke patiënt dat de
homeostase zonder interventie niet gehandhaafd kan worden. MODS kenmerkt
zich door het achtereenvolgens ontregelen van verschillende orgaansystemen,
meestal beginnend met de longen. Dit wordt gevolgd door functieverlies van de
lever, het darmstelsel, de nieren en uiteindelijk het hart, hoewel de exacte
volgorde kan variëren onder invloed van onderliggende ziekten of de aard van
het voorafgaande insult. MODS kan optreden na diverse fysiologische insulten,
onder andere pancreatitis, trauma, brandwonden, shock, ernstige infecties,
meervoudige bloedtransfusies en longcontusies. Er zijn twee klinische
observaties die sterk suggereren dat MODS een systemisch proces is. Ten eerste
zijn de organen waar schade optreedt niet noodzakelijkerwijs betrokken bij het
primaire ziekteproces. Ten tweede is er vaak een tijdsinterval van dagen tot
weken tussen het primaire insult en het ontstaan van orgaandisfunctie elders in
het lichaam. Deze waarnemingen suggereren dat endogene factoren in de
circulatie betrokken zijn bij de pathofysiologie van MODS. Studies bij patiënten
in kritieke toestand laten zien dat een toegenomen concentratie van
proinflammatoire cytokinen samenhangt met orgaanfalen en een verhoogde kans
op overlijden. Het wordt nu algemeen aanvaard dat MODS het resultaat is van
een gegeneraliseerde ontstekingsreactie (hoofdstuk 1).
Onderzoek naar de onderliggende mechanismen bij MODS vereist invasieve
procedures die niet uitgevoerd kunnen worden bij mensen. Om opheldering te
krijgen over de pathofysiologie zijn daarom dierexperimenten en in vitro studies
noodzakelijk. In ons laboratorium is een diermodel voor MODS ontwikkeld. Het
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wordt het zymosan-induced generalized inflammation (ZIGI) model genoemd en
is ook overgenomen door andere onderzoeksgroepen (hoofdstuk 2).
Een intraperitoneale injectie van zymosan in C57BL/6 muizen leidt tot een drie-
fasisch ziektebeeld, beginnend met een peritonis-achtige reactie. In deze eerste
fase, die twee dagen duurt, zijn de dieren erg ziek, hetgeen blijkt uit een
tijdelijke afname in lichaamstemperatuur, een afname van het lichaamsgewicht,
en een mortaliteit van maximaal 20%. Na 2 dagen lijken de overlevende muizen
te herstellen, de lichaamstemperatuur en het lichaamsgewicht normaliseren
weer. Na ongeveer 7 dagen begint de derde fase. Deze fase wordt
gekarakteriseerd door MODS-achtige signalen, namelijk cachexie, tachypnoe en
hypothermie. Tevens treden progressieve veranderingen in de morfologie van de
longen, lever, milt en nieren op, die ook weerspiegeld worden door een toename
van de orgaangewichten. In de longen treden bloedingen op die zich
ontwikkelen tot grote, macroscopisch zichtbare, bloeduitstortingen. Dit proces
kan gekwantificeerd worden door gebruik te maken van een longscore. In deze
fase sterven nog eens 20-30% van de dieren, alvorens het experiment na 12 tot
22 dagen beëindigd wordt.
Veel onderzoek heeft zich gericht op het identificeren van de mediatoren die
betrokken zijn bij het ontstaan van MODS. Ontstekingsmediatoren in de
circulatie zijn relatief gemakkelijk te meten, maar het is de vraag in hoeverre
deze metingen een juiste weerspiegeling zijn van processen op orgaanniveau,
waar de schade optreedt. Om logische interventies te bedenken, die mogelijk
gericht zijn tegen meerdere cytokines, is het nodig om data te verzamelen over
de expressie van deze cytokines op orgaanniveau gedurende het ontstaan van
MODS. Daarom hebben we een uitgebreide studie verricht waarin we het beloop
van de expressie van TNF-α, IL-1β, IL-6, MIF, IL-12, IFN-γ en IL-10 mRNA
onderzocht hebben in de longen, lever, milt en nieren (hoofdstuk 3). Dit zijn
weefsels die in de loop van de tijd een toenemende mate van histopathologische
veranderingen laten zien. Tijdens de peritonitisfase bleef de opregulatie van
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cytokine mRNA beperkt. Tijdens de periode van ogenschijnlijk herstel nam de
expressie van cytokine mRNA sterk toe, waarbij het maximum meestal bereikt
werd op dag 9, toen de verslechtering van de klinische toestand al was
begonnen. De opregulering van TNF-α mRNA was het meest uitgesproken,
vooral in de longen en de lever. Interventies moeten dus bij voorkeur gericht zijn
tegen meerdere cytokines en in dit model lijkt er in elk geval een ruime
tijdsperiode na het primaire insult beschikbaar waarin behandeling kan
plaatsvinden.
Eerder onderzoek in ons laboratorium heeft aangetoond dat TNF-α spiegels in
het plasma verhoogd zijn in de eerste 24 uur na injectie van zymosan, gevolgd
door een opvallende piek vanaf dag 8. Daarnaast hebben vervolgexperimenten
met het model aangetoond dat interventies gericht tegen TNF-α de symptomen
van MODS kunnen afzwakken, hetgeen laat zien dat TNF-α een prominente rol
speelt in de pathofysiologie. Aanvullend bewijs voor deze hypothese wordt
geleverd door experimenten met TNF knockout-muizen. De volledige
afwezigheid van TNF resulteert in een significant lagere sterfte in het ZIGI
model (hoofdstuk 4). Daarnaast hebben TNF knockout-muizen op dag 22 een
hogere gemiddelde lichaamstemperatuur en een hoger gemiddeld
lichaamsgewicht dan de muizen van het wildtype. Overlevende dieren van beide
groepen vertonen dan echter aanzienlijke en vergelijkbare microscopische
schade in longen, lever en milt en een verhoogd orgaangewicht. Hoewel TNF-
deficiënte muizen dus een significante verbetering laten zien in morbiditeit en
mortaliteit, beschermt de afwezigheid van TNF blijkbaar niet volledig tegen de
symptomen van MODS die door zymosan opgewekt worden.
Aangezien strategieën gericht tegen de werking van alleen TNF-α tot nu toe
slechts ten dele succesvol gebleken zijn in het voorkomen van MODS in het
muizenmodel, lijkt het aannemelijk dat er meer winst te boeken valt bij
interventies die gericht zijn tegen meerdere cytokines tegelijkertijd.
Pentoxifylline (PTX) is een methylxanthinederivaat dat gebruikt wordt bij de
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behandeling van chronische occlusieve arteriële aandoeningen vanwege zijn
reologische werking. Daarnaast heeft PTX effecten op de ontstekingsreactie. Er
is aangetoond dat het TNF-α, IL-1β en IL-6 spiegels in sepsismodellen kan
verlagen. Het is bekend dat PTX fosfodiësterase remt, waardoor cyclisch
adenosine monofosfaatspiegels in het cytoplasma verhoogd worden. Dit laatste
remt sterk de genexpressie van TNF-α. Omdat PTX meerdere proinflammatoire
cytokines tegelijkertijd kan tegenwerken is het mogelijk een geschikt middel om
de gegeneraliseerde ontstekingsreactie die tot orgaanfalen leidt af te zwakken.
We hebben een interventiestudie uitgevoerd waarin de effecten van PTX
toediening onderzocht werden (hoofdstuk 5). Ex vivo remt PTX de door LPS
geïnduceerde productie van TNF-α en IL-6 (maar niet van IL-1β) in J774.A1
macrofagen op een dosisafhankelijke manier, zowel op mRNA als op
eiwitniveau. Wanneer zymosan-behandelde C57BL/6 muizen PTX toegediend
krijgen, resulteert dit niet in een significant verbeterde overleving,
lichaamstemperatuur, lichaamsgewicht of longscore. Ook zijn er geen
significante verschillen in orgaangewichten gevonden tussen muizen die PTX
kregen en muizen die PBS kregen. De TNF-α en IL-6 mRNA expressie in de
lever is vergelijkbaar in beide groepen en dit is waarschijnlijk de belangrijkste
oorzaak voor het uitblijven van positieve effecten op de morbiditeit en
mortaliteit. Bij elkaar genomen bieden deze resultaten dus geen steun voor de
hypothese dat PTX positieve effecten heeft bij de orgaanschade die door
zymosan wordt opgewekt.
Tijdens ontstekingen en shock kunnen proinflammatoire cytokines en
componenten van bacteriële celwanden het enzym nitric oxide synthase (iNOS)
induceren. Het NO geproduceerd door iNOS wordt verondersteld weefselschade
te veroorzaken, direct danwel indirect door de vorming van peroxynitriet. Wij
hebben de rol van iNOS in het ontstaan van MODS bij muizen onderzocht door
gebruik te maken van zowel een selectieve iNOS-remmer (aminoguanidine) als
iNOS knockout-muizen (hoofdstuk 6). Kwantitatieve reverse transcriptase
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polymerase chain reaction (RT-PCR) en immunohistochemie laten een sterk
verhoogde expressie van iNOS messenger RNA (mRNA) en iNOS eiwit zien in
de levers van C57BL/6 muizen in de derde – MODS-achtige- fase van het
model. De in vivo toediening van aminoguanidine aan C57BL/6 muizen en de
volledige afwezigheid van iNOS enzym (iNOS knockout-muizen) hebben echter
geen van beide een gunstig effect op overleving, lichaamsgewicht en
lichaamstemperatuur. Het long-, lever-, en miltgewicht en de longscores van de
verschillende experimentele groepen zijn onderling vergelijkbaar. Deze
resultaten pleiten sterk tegen een essentiële en oorzakelijke rol van iNOS bij het
ontstaan van MODS bij muizen.
De extracellulaire matrix speelt een centrale rol in de structuur van weefsels en
bij het instandhouden van homeostase. Het uiteenvallen van de
weefselarchitectuur resulteert in orgaanfalen. Het remodelleren van de
extracellulaire matrix, hetzij als onderdeel van de fysiologische homeostase en
ontwikkeling hetzij als onderdeel van een pathologisch proces, gebeurt voor een
groot deel door enzymen van de matrix metalloproteinase (MMP) familie, die
bestaat uit een groeiend aantal gesecreteerde en membraangebonden
metalloendopeptidasen. Bij ontstekingen spelen ze een belangrijke rol bij de
interactie van cellen met hun omgeving. Bij diverse inflammatoire aandoeningen
worden MMP’s gedacht betrokken te zijn bij optredende weefselschade. MMP’s
worden ook in verband gebracht met systemische ontstekingen. Diverse
onderzoeken suggereren dat MMP’s een belangrijke rol spelen in het ontstaan
van het adult respiratory distress syndrome (ARDS) en onlangs is aangetoond
dat MMP-9 concentraties in de circulatie verhoogd zijn bij patiënten in kritieke
toestand. Het is aannemelijk dat overactivatie van MMP’s kan bijdragen aan de
orgaanschade die bij MODS wordt waargenomen. De genexpressie van MMP’s
wordt gereguleerd door diverse factoren, waaronder cytokines. Er is een
experiment gedaan waarbij de expressie en activiteit van verschillende
gelatinases en collagenases werd bepaald in de lever, long, milt en nieren tijdens
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MODS opgewekt door zymosan (hoofdstuk 7). De expressie van MMP-2
mRNA in leverweefsel van zymosan-behandelde muizen is sterk opgereguleerd.
Voor MMP-9 is dit het geval voor alle onderzochte organen. In de lever, de
longen, maar met name in de milt van zymosan-behandelde muizen wordt een
significante toename van de activiteit van zowel pro- als actief MMP-2 en –9
gezien naarmate de tijd vordert. De activiteit van MMP-1 en –13 is erg laag in
alle lever- en longmonsters. In de milten van zymosan-behandelde muizen wordt
echter een hoge activiteit van MMP-1 en –13 waargenomen. Specifieke
immuunkleuring voor MMP-2 wordt gezien in de lever en de milt, maar niet in
de longen en in de nieren van zymosan-behandelde dieren. Kleuring voor MMP-
9 is aanwezig in lever-, long- en miltweefsel van zymosan-behandelde muizen.
Voor beide MMP’s lijkt de kleuring beperkt te blijven tot fagocyten. Deze
resultaten suggereren dat MMP’s, vooral MMP-9, een rol spelen in de
pathogenese van MODS. Interventiestudies met MMP-remmers zouden
aanvullend bewijs voor deze hypothese kunnen leveren.
Aangezien MODS niet door één enkele mediator veroorzaakt lijkt te worden,
lijken interventies gericht tegen meerdere mediatoren tegelijkertijd de meest
hoopgevende benadering voor de toekomst. Het vinden of ontwerpen van
substanties die meerdere mediatoren op een specifieke manier kunnen
beïnvloeden zal hierbij een belangrijk onderwerp zijn. Eerdere studies die
gericht waren tegen meerdere mediatoren zijn uitgevoerd met niet-specifieke
behandelingen, terwijl biologische werkingsmechanismen van de gebruikte
substanties vaak niet geheel duidelijk zijn; dit maakt het trekken van harde
conclusies moeilijk. Hopelijk zullen specifieke interventies in de nabije
toekomst mogelijk zijn, zoals het remmen van meerdere proinflammatoire
cytokines tegelijkertijd, zonder andere cellulaire processen te beïnvloeden. Dit
soort studies zal ons begrip van de onderliggende pathofysiologie van MODS
verbeteren en zal uiteindelijk leiden tot betere behandelmethoden bij patiënten
met (het risico op) MODS.
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Promoveren doe je allerminst alleen, en daarom is een woord van dank op zijn
plaats aan iedereen die op enigerlei wijze heeft bijgedragen aan de
totstandkoming van dit proefschrift. Laat ik allereerst mijn promotor, professor
Goris, en co-promotor, professor Van de Meer, bedanken. Professor Goris, u
staat aan de basis van dit proefschrift. Als “grote initiator” van het ZIGI model
bent u al vanaf de jaren ’80 betrokken bij al het onderzoek dat op de afdeling
met dit model plaatsvindt. Deze onderzoeken vormden de basis van waaruit ik
kon vertrekken toen ik aan mijn onderzoek begon. Als chirurg bood u mij ook
een frisse kijk vanuit een klinisch oogpunt, daar waar ik alleen kon buigen op
laboratorium- en boekenwijsheid. Bedankt voor de prettige samenwerking.
Professor Van der Meer, bedankt voor de adviezen op cytokinengebied. Het valt
niet mee om met een vooropleiding als voedingskundige wegwijs te worden in
de wondere wereld der cytokinen. De wekelijkse cytokinenbesprekingen hebben
zeker bijgedragen aan meer begrip op dit gebied mijnerzijds.
Het hebben van leuke collega’s vind ik een van de belangrijkste aspecten die
van invloed zijn op de arbeidsvreugde, en ik vind dat ik daarbij op het lab van de
Heelkunde erg geboft heb. Ik heb het lab al vanaf het begin leren kennen als een
gezellig mannenclubje met wie het ook buiten werktijd goed toeven is.
Thijs Hendriks, jij bent als mijn directe begeleider de belangrijkste persoon
geweest bij het tot een goed resultaat brengen van mijn onderzoek. Jouw
kritische doch pragmatische manier van denken gaf mij de sturing die ik nodig
had en bij het schrijven van artikelen zag jouw Engelse taalgebruik er toch
telkens professioneler uit dan mijn aanvankelijke tekst, waardoor de
leesbaarheid (en de publiceerbaarheid!) van de manuscripten aanmerkelijk
toenam. Mijn dank hiervoor.
Erwin Waas en Arjan Nooteboom, wij hebben op ons AIO-kamertje samen erg
veel lol gehad en heel wat lief en leed gedeeld, vaak op tijdstippen waarop we
ook hard aan onze promotie hadden kunnen werken. Echter ook daarbuiten
hebben we veel tijd met elkaar doorgebracht. Erwin, vooral in de eerste jaren
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van mijn onderzoek zijn we regelmatig de bioscoop, kroeg, of beide ingedoken.
Ik heb je in de loop der tijd erg leren waarderen ondanks, of misschien wel
dankzij, het feit dat we vaak anders tegen dingen aankijken. Arjan, jij weet
balorigheid tot kunst te verheffen. Dat merkte ik voor het eerst op het congres in
Muenchen (ik heb zelden zo gelachen), maar natuurlijk ook later, toen we samen
de aap gingen uithangen in een bandje. Jongens, jullie zijn mijn vrienden
geworden en ik hoop dat we onze vriendschap ook na onze promoties kunnen
voortzetten (ik eis op zijn minst een jaarlijks in de winter terugkerend
“doctorweekend”!).
Ben de Man en Roger Lomme, wat zou het lab zijn zonder jullie? De hulp die ik
van jullie heb gekregen omvat zoveel verschillende dingen… Roger, vooral de
laatste periode heb je me veel geholpen met werkzaamheden waar ik niet altijd
tijd voor, zin in, of de mogelijkheid toe had. Ben, jij hebt me wegwijs gemaakt
in het werken met muizen en je hebt me heel vaak geholpen bij de
werkzaamheden op het dierenlab, die niet zelden in de weekenden plaatsvonden.
Bedankt jongens, natuurlijk ook voor de gezellige koffiepauzes waarvoor jullie
doorgaans stipt om 10 en 3 uur op de AIO-kamer kwamen aankloppen
(“labwerk is een kwestie van goed plannen”).
Ik heb ook veel hulp gekregen van mensen van andere afdelingen van het UMC
St Radboud. Ongeveer tien jaar geleden luisterde ik, zittend in Wageningse
collegebanken, naar de verhalen van een vriendelijke man met guitig
samengeknepen oogjes, niet wetend dat het ooit nog tot een professionele
samenwerking zou komen. Deze man, Albert Verhofstad, wil ik graag bedanken
voor zijn bijdrage aan het beoordelen van microscopische kleuringen en zijn
adviezen hieromtrent, maar natuurlijk ook voor zijn bijdrage aan mijn teksten.
Ook wil ik Vincent en Anneke van het pathologielab bedanken voor hun
praktische hulp bij de kleuringen en het nemen van histologische foto’s. Ik heb
ook kleuringen verricht op het lab van (inmiddels professor) Joost Schalkwijk,
waar Ivonne van Vlijmen en Mieke Bergers mij op weg hielpen met de
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kleuringen en Joost me regelmatig bijgestaan heeft bij het beoordelen van de
resultaten. Hartelijk bedankt hiervoor.
Ik wil verder iedereen op het lab van de algemene interne geneeskunde
bedanken, met name Anneke Hijmans voor het mij bijbrengen van de
grondbeginselen van de PCR-techniek en Ineke Verschueren voor haar RIA- en
ELISA-bepalingen. Ik ben ook heel veel dank verschuldigd aan Louis van der
Locht van het CHL. Louis, de keren dat ik (en vele anderen) met PCR-
problemen bij jou ben komen aankloppen zijn talrijk. Steeds nam je de tijd voor
me, terwijl je natuurlijk ook druk was met je eigen werkzaamheden. Mensen
zoals jij, die verder kijken dan de belangen van alleen hun eigen afdeling, maken
het Radboud als collectief sterker. Ik waardeer deze werkhouding zeer.
Ik ben ook dank verschuldigd aan Geert Poelen en de andere medewerkers van
de SPF unit op het dierenlab. Jullie zijn altijd erg behulpzaam geweest en deden
nooit ergens moeilijk over, dat is helaas vaak anders. Bedankt hiervoor. Michel
van der Jagt, fuule gak, bedankt voor je bijdrage aan het iNOS-artikel. Je was de
meest kleurrijke student die stage heeft gelopen op het lab in de periode dat ik er
werkzaam was.  Ik heb je humor erg gewaardeerd, en daarnaast ben je natuurlijk
ook gewoon een erg aardige kerel.
Monique Jansen,  mijn “voorgangster in het ZIGI model”, jij hebt me meer
geholpen dan je zelf waarschijnlijk beseft.  Ik heb voortgebouwd op jouw werk,
en aangezien het makkelijker is op een rijdende trein te springen dan hem zelf
aan te duwen, heb ik bij mijn onderzoek weinig opstartproblemen gehad. Ook
was het bij het schrijven van artikelen fijn om de kunst een beetje bij jou af te
kijken. Dankjewel.
Dan zijn er tot slot nog mensen uit mijn privéleven wier morele steun op
indirecte wijze heeft bijgedragen aan de totstandkoming van dit proefschrift. Het
zou misschien wel geschreven zijn, maar zonder hen zou er niets aan geweest
zijn! Martin, als iedere boom die wij over het leven opgezet hebben een echte
zou zijn, zou niemand zich nog druk hoeven maken over het tropisch
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regenwoud. Mark, het blijft na al die jaren inspirerend om jou als vriend te
hebben. Never a dull moment…Luce, al vanaf het begin was het gezellig samen,
hulde aan de “mannenvrouwen”! “Johan de droomeconoom”, altijd in voor voor
gezelligheid en een biertje. Dank ook aan Jan-Willem, Wouter, (en nogmaals
Arjan) voor de geweldige muzikale uitspattingen op de maandagavonden en de
gezelligheid daaromheen. Jolie, Wouter (No.2), Kata, Sanne en Judith, bedankt
voor de leuke tijd aan de Azaleastraat. Judith (no.2), wie had verwacht dat een
cursus proefdierkunde romantiek zou kunnen opwekken? Bedankt voor de fijne
tijd.
Thuis ligt de basis. Papa, mama en Johan, wie zou ik zijn geworden zonder
jullie? De invloed die jullie hebben gehad op mijn ontwikkeling kan nauwelijks
overschat worden. Dank jullie wel!
Ik heb de belangrijkste persoon tot het laatst bewaard: Annelieke, ik had nooit
gedacht dat jij zou bestaan. Sinds ik jou ken voel ik mij een ander mens. Een
beter mens. Ik voel mij ontzettend dankbaar dat ik mijn leven met jou mag
delen.
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